Genome	O
-	O
Wide	O
Expression	O
of	O
Azoospermia	B-DS
Testes	O
Demonstrates	O
a	O
Specific	O
Profile	O
and	O
Implicates	O
ART3	B-GP
in	O
Genetic	O
Susceptibility	O

Infertility	B-DS
affects	O
about	O
one	O
in	O
six	O
couples	O
attempting	O
pregnancy	O
,	O
with	O
the	O
man	B-OG
responsible	O
in	O
approximately	O
half	O
of	O
the	O
cases	O
.	O

Because	O
the	O
pathophysiology	O
underlying	O
azoospermia	B-DS
is	O
not	O
elucidated	O
,	O
most	O
male	B-DS
infertility	I-DS
is	O
diagnosed	O
as	O
idiopathic	O
.	O

Genome	O
-	O
wide	O
gene	O
expression	O
analyses	O
with	O
microarray	O
on	O
testis	O
specimens	O
from	O
47	O
non	O
-	O
obstructive	O
azoospermia	B-DS
(	O
NOA	O
)	O
and	O
11	O
obstructive	O
azoospermia	B-DS
(	O
OA	O
)	O
patients	O
were	O
performed	O
,	O
and	O
2	O
,	O
611	O
transcripts	O
that	O
preferentially	O
included	O
genes	O
relevant	O
to	O
gametogenesis	O
and	O
reproduction	O
according	O
to	O
Gene	O
Ontology	O
classification	O
were	O
found	O
to	O
be	O
differentially	O
expressed	O
.	O

Using	O
a	O
set	O
of	O
945	O
of	O
the	O
2	O
,	O
611	O
transcripts	O
without	O
missing	O
data	O
,	O
NOA	O
was	O
further	O
categorized	O
into	O
three	O
classes	O
using	O
the	O
non	O
-	O
negative	O
matrix	O
factorization	O
method	O
.	O

Two	O
of	O
the	O
three	O
subclasses	O
were	O
different	O
from	O
the	O
OA	O
group	O
in	O
Johnsen	O
'	O
s	O
score	O
,	O
FSH	B-GP
level	O
,	O
and	O
/	O
or	O
LH	B-GP
level	O
,	O
while	O
there	O
were	O
no	O
significant	O
differences	O
between	O
the	O
other	O
subclass	O
and	O
the	O
OA	O
group	O
.	O

In	O
addition	O
,	O
the	O
52	O
genes	O
showing	O
high	O
statistical	O
difference	O
between	O
NOA	O
subclasses	O
(	O
p	O
<	O
0	O
.	O
01	O
with	O
Tukey	O
'	O
s	O
post	O
hoc	O
test	O
)	O
were	O
subjected	O
to	O
allelic	O
association	O
analyses	O
to	O
identify	O
genetic	O
susceptibilities	O
.	O

After	O
two	O
rounds	O
of	O
screening	O
,	O
SNPs	O
of	O
the	O
ADP	B-GP
-	I-GP
ribosyltransferase	I-GP
3	I-GP
gene	O
(	O
ART3	B-GP
)	O
were	O
associated	O
with	O
NOA	O
with	O
highest	O
significance	O
with	O
ART3	B-GP
-	O
SNP25	O
(	O
rs6836703	O
;	O
p	O
=	O
0	O
.	O
0025	O
)	O
in	O
442	O
NOA	O
patients	O
and	O
475	O
fertile	O
men	O
.	O

Haplotypes	O
with	O
five	O
SNPs	O
were	O
constructed	O
,	O
and	O
the	O
most	O
common	O
haplotype	O
was	O
found	O
to	O
be	O
under	O
-	O
represented	O
in	O
patients	O
(	O
NOA	O
26	O
.	O
6	O
%	O
versus	O
control	O
35	O
.	O
3	O
%,	O
p	O
=	O
0	O
.	O
000073	O
).	O

Individuals	O
having	O
the	O
most	O
common	O
haplotype	O
showed	O
an	O
elevated	O
level	O
of	O
testosterone	O
,	O
suggesting	O
a	O
protective	O
effect	O
of	O
the	O
haplotype	O
on	O
spermatogenesis	O
.	O

Thus	O
,	O
genome	O
-	O
wide	O
gene	O
expression	O
analyses	O
were	O
used	O
to	O
identify	O
genes	O
involved	O
in	O
the	O
pathogenesis	O
of	O
NOA	O
,	O
and	O
ART3	B-GP
was	O
subsequently	O
identified	O
as	O
a	O
susceptibility	O
gene	O
for	O
NOA	O
.	O

These	O
findings	O
clarify	O
the	O
molecular	O
pathophysiology	O
of	O
NOA	O
and	O
suggest	O
a	O
novel	O
therapeutic	O
target	O
in	O
the	O
treatment	O
of	O
NOA	O
.	O

Author	O
Summary	O

Worldwide	O
,	O
approximately	O
15	O
%	O
of	O
couples	O
attempting	O
pregnancy	O
meet	O
with	O
failure	O
.	O

Male	O
factors	O
are	O
thought	O
to	O
be	O
responsible	O
in	O
20	O
%–	O
50	O
%	O
of	O
all	O
infertility	B-DS
cases	O
.	O

Azoospermia	B-DS
,	O
the	O
absence	O
of	O
sperm	O
in	O
the	O
ejaculate	O
due	O
to	O
defects	O
in	O
its	O
production	O
or	O
delivery	O
is	O
common	O
in	O
male	B-DS
infertility	I-DS
.	O

In	O
this	O
study	O
,	O
we	O
focused	O
on	O
non	O
-	O
obstructive	O
azoospermia	B-DS
(	O
NOA	O
)	O
because	O
the	O
etiologies	O
of	O
obstructive	O
azoospermia	B-DS
are	O
well	O
studied	O
and	O
distinct	O
from	O
those	O
of	O
NOA	O
.	O

Microdeletions	O
of	O
the	O
Y	O
chromosome	O
are	O
thus	O
far	O
the	O
only	O
genetic	O
defects	O
known	O
to	O
affect	O
human	B-OG
spermatogenesis	O
,	O
but	O
most	O
cases	O
of	O
NOA	O
are	O
unsolved	O
.	O

Because	O
NOA	O
results	O
from	O
a	O
variety	O
of	O
defects	O
in	O
the	O
developmental	O
stages	O
of	O
spermatogenesis	O
,	O
the	O
stage	O
-	O
specific	O
expressions	O
of	O
genes	O
in	O
the	O
testes	O
must	O
be	O
investigated	O
.	O

Thus	O
,	O
genome	O
-	O
wide	O
gene	O
expression	O
analyses	O
of	O
testes	O
of	O
NOA	O
can	O
provide	O
insight	O
into	O
the	O
several	O
etiologies	O
and	O
genetic	O
susceptibilities	O
of	O
NOA	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
analyzed	O
several	O
differentially	O
expressed	O
genes	O
in	O
NOA	O
subclasses	O
and	O
identified	O
ART3	B-GP
as	O
a	O
susceptibility	O
gene	O
for	O
NOA	O
.	O

Introduction	O

Spermatogenesis	O
,	O
a	O
major	O
function	O
of	O
mammalian	O
testes	O
,	O
is	O
complex	O
and	O
strictly	O
regulated	O
.	O

While	O
spermatogenesis	O
is	O
a	O
maturation	O
of	O
germ	O
cells	O
,	O
other	O
cells	O
including	O
Sertoli	O
,	O
Leydig	O
,	O
and	O
peritubular	O
myoid	O
cells	O
also	O
play	O
important	O
roles	O
,	O
and	O
defects	O
at	O
any	O
differentiation	O
stage	O
might	O
result	O
in	O
infertility	B-DS
.	O

Male	B-DS
infertility	I-DS
is	O
estimated	O
to	O
affect	O
about	O
5	O
%	O
of	O
adult	O
human	B-OG
males	O
,	O
but	O
75	O
%	O
of	O
the	O
cases	O
are	O
diagnosed	O
as	O
idiopathic	O
because	O
the	O
molecular	O
mechanisms	O
underlying	O
the	O
defects	O
have	O
not	O
been	O
elucidated	O
.	O

In	O
consequence	O
,	O
an	O
estimated	O
one	O
in	O
six	O
couples	O
experiences	O
difficulty	O
in	O
conceiving	O
a	O
child	O
despite	O
advances	O
in	O
assisted	O
reproductive	O
technologies	O
.	O

Male	O
-	O
factor	O
infertility	B-DS
constitutes	O
about	O
half	O
of	O
the	O
cases	O
,	O
and	O
a	O
significant	O
proportion	O
of	O
male	B-DS
infertility	I-DS
is	O
accompanied	O
by	O
idiopathic	O
azoospermia	B-DS
or	O
severe	O
oligozoospermia	B-DS
,	O
which	O
may	O
well	O
have	O
potential	O
genetic	O
components	O
.	O

It	O
is	O
well	O
-	O
recognized	O
that	O
men	O
with	O
very	O
low	B-DS
sperm	I-DS
counts	I-DS
(<	O
1	O
million	O
/	O
ml	O
),	O
identified	O
through	O
an	O
infertility	B-DS
clinic	O
,	O
have	O
a	O
higher	O
incidence	O
of	O
Y	O
-	O
chromosome	O
microdeletion	O
(	O
up	O
to	O
17	O
%)	O
[	O
1	O
,	O
2	O
].	O

However	O
,	O
the	O
genetic	O
causalities	O
of	O
most	O
cases	O
of	O
azoospermia	B-DS
are	O
not	O
known	O
.	O

Global	O
gene	O
-	O
expression	O
profiling	O
with	O
microarray	O
technologies	O
has	O
been	O
applied	O
with	O
great	O
promise	O
to	O
monitor	O
biological	O
phenomena	O
and	O
answer	O
biological	O
questions	O
.	O

Indeed	O
,	O
microarray	O
technologies	O
have	O
been	O
successfully	O
used	O
to	O
identify	O
biomarkers	O
,	O
disease	O
subtypes	O
,	O
and	O
mechanisms	O
of	O
toxicity	O
.	O

We	O
applied	O
microarray	O
analysis	O
to	O
testis	O
specimens	O
from	O
infertile	B-DS
individuals	O
including	O
patients	O
with	O
obstructive	O
azoospermia	B-DS
(	O
OA	O
)	O
and	O
non	O
-	O
obstructive	O
azoospermia	B-DS
(	O
NOA	O
[	O
OMIM	O
%	O
606766	O
])	O
to	O
characterize	O
NOA	O
and	O
to	O
identify	O
the	O
specific	O
pathophysiology	O
and	O
molecular	O
pathways	O
of	O
the	O
disease	O
.	O

In	O
addition	O
,	O
we	O
attempted	O
to	O
identify	O
genetic	O
susceptibility	O
to	O
NOA	O
from	O
genes	O
differentially	O
expressed	O
in	O
NOA	O
testes	O
.	O

Genes	O
related	O
to	O
spermatogenesis	O
and	O
candidate	O
genes	O
for	O
azoospermia	B-DS
have	O
been	O
surveyed	O
in	O
humans	B-OG
and	O
mice	B-OG
,	O
especially	O
since	O
gene	O
targeting	O
technology	O
accelerated	O
the	O
identification	O
of	O
genes	O
that	O
play	O
crucial	O
roles	O
in	O
spermatogenesis	O
[	O
3	O
].	O

Because	O
spermatogenesis	O
is	O
a	O
complex	O
process	O
including	O
meiosis	O
,	O
a	O
germ	O
cell	O
–	O
specific	O
event	O
,	O
gene	O
expression	O
profiles	O
specific	O
to	O
the	O
differentiation	O
stage	O
,	O
clinically	O
classified	O
by	O
the	O
Johnsen	O
'	O
s	O
score	O
,	O
were	O
examined	O
to	O
provide	O
insight	O
into	O
the	O
pathogenesis	O
of	O
azoospermia	B-DS
[	O
4	O
].	O

In	O
the	O
current	O
study	O
,	O
we	O
performed	O
microarray	O
analyses	O
on	O
biopsied	O
testes	O
obtained	O
from	O
47	O
NOA	O
patients	O
at	O
diverse	O
clinical	O
stages	O
without	O
prior	O
selection	O
and	O
11	O
OA	O
patients	O
.	O

The	O
47	O
NOA	O
samples	O
showed	O
a	O
wide	O
range	O
of	O
heterogeneity	O
,	O
including	O
a	O
series	O
of	O
impairments	O
at	O
the	O
differentiation	O
stage	O
of	O
spermatogenesis	O
that	O
so	O
far	O
have	O
been	O
evaluated	O
mainly	O
by	O
pathological	O
findings	O
.	O

Thus	O
,	O
classification	O
of	O
NOA	O
at	O
the	O
transcriptome	O
level	O
is	O
a	O
necessary	O
first	O
step	O
in	O
elucidation	O
of	O
the	O
molecular	O
pathogenesis	O
of	O
NOA	O
.	O

To	O
do	O
this	O
,	O
we	O
adopted	O
the	O
non	O
-	O
negative	O
matrix	O
factorization	O
(	O
NMF	O
)	O
method	O
,	O
an	O
unsupervised	O
classification	O
algorithm	O
developed	O
for	O
decomposing	O
images	O
that	O
has	O
been	O
applied	O
in	O
various	O
fields	O
of	O
science	O
including	O
bioinformatics	O
because	O
of	O
its	O
potential	O
for	O
providing	O
insight	O
into	O
complex	O
relationships	O
in	O
large	O
data	O
sets	O
[	O
5	O
–	O
7	O
].	O

47	O
of	O
the	O
NOA	O
-	O
samples	O
were	O
divided	O
into	O
three	O
subclasses	O
by	O
the	O
NMF	O
method	O
,	O
and	O
each	O
class	O
was	O
associated	O
with	O
clinical	O
features	O
.	O

149	O
transcripts	O
were	O
identified	O
as	O
differentially	O
expressed	O
genes	O
among	O
the	O
NOA	O
subclasses	O
according	O
to	O
a	O
statistical	O
criterion	O
,	O
and	O
the	O
features	O
involved	O
in	O
spermatogenesis	O
based	O
on	O
Gene	O
Ontology	O
classification	O
were	O
demonstrated	O
.	O

The	O
genetic	O
causality	O
of	O
NOA	O
most	O
likely	O
involves	O
the	O
expression	O
level	O
of	O
a	O
susceptibility	O
gene	O
,	O
which	O
might	O
be	O
detected	O
by	O
genome	O
-	O
wide	O
gene	O
expression	O
analysis	O
.	O

While	O
it	O
is	O
daunting	O
to	O
identify	O
genetic	O
susceptibility	O
from	O
100	O
-	O
1000	O
differentially	O
expressed	O
genes	O
,	O
genetic	O
susceptibility	O
might	O
more	O
readily	O
be	O
identified	O
from	O
random	O
genes	O
differentially	O
expressed	O
with	O
high	O
significance	O
rather	O
than	O
by	O
investigating	O
only	O
genes	O
in	O
a	O
specific	O
biological	O
pathway	O
.	O

Based	O
on	O
a	O
well	O
-	O
defined	O
statistical	O
procedure	O
,	O
52	O
candidate	O
genes	O
for	O
NOA	O
were	O
catalogued	O
by	O
gene	O
expression	O
profile	O
and	O
screened	O
for	O
allelic	O
association	O
study	O
in	O
a	O
total	O
of	O
442	O
NOA	O
patients	O
and	O
475	O
fertile	O
male	O
controls	O
.	O

After	O
gene	O
-	O
centric	O
selection	O
of	O
SNPs	O
,	O
191	O
SNPs	O
of	O
42	O
candidate	O
genes	O
were	O
initially	O
evaluated	O
for	O
allelic	O
association	O
with	O
NOA	O
.	O

After	O
two	O
rounds	O
of	O
screening	O
,	O
SNPs	O
of	O
the	O
ADP	B-GP
-	I-GP
ribosyltransferase	I-GP
3	I-GP
(	O
ART3	B-GP
)	O
gene	O
were	O
found	O
to	O
be	O
significantly	O
associated	O
with	O
NOA	O
,	O
and	O
five	O
of	O
these	O
SNPs	O
were	O
selected	O
for	O
haplotype	O
construction	O
.	O

The	O
most	O
common	O
haplotype	O
was	O
significantly	O
under	O
-	O
represented	O
in	O
the	O
patients	O
and	O
may	O
be	O
protective	O
.	O

The	O
functional	O
impact	O
of	O
this	O
haplotype	O
was	O
further	O
investigated	O
.	O

Results	O

Extraction	O
of	O
NOA	O
-	O
Related	O
Gene	O
Expression	O
Profile	O

As	O
shown	O
in	O
Figure	O
1A	O
,	O
the	O
most	O
notable	O
difference	O
in	O
histological	O
findings	O
between	O
NOA	O
and	O
OA	O
testes	O
was	O
that	O
the	O
NOA	O
patients	O
exhibited	O
,	O
at	O
varying	O
degrees	O
,	O
incomplete	O
sets	O
of	O
spermatogenic	O
germ	O
cells	O
(	O
spermatogonia	O
,	O
spermatocytes	O
,	O
spermatids	O
,	O
and	O
spermatozoa	O
)	O
in	O
the	O
seminiferous	O
tubules	O
.	O

In	O
severe	O
NOA	O
patients	O
,	O
we	O
could	O
not	O
even	O
detect	O
Sertoli	O
cells	O
,	O
the	O
major	O
somatic	O
cells	O
of	O
the	O
seminiferous	O
tubules	O
,	O
on	O
histological	O
examination	O
(	O
figure	O
not	O
shown	O
),	O
indicating	O
clinical	O
heterogeneity	O
of	O
NOA	O
testes	O
.	O

In	O
order	O
to	O
elucidate	O
the	O
molecular	O
systems	O
underlying	O
NOA	O
at	O
the	O
transcriptome	O
level	O
,	O
it	O
is	O
important	O
to	O
extract	O
genes	O
reflecting	O
the	O
diversity	O
of	O
NOA	O
phenotypes	O
.	O

For	O
this	O
purpose	O
,	O
we	O
first	O
compared	O
global	O
gene	O
expression	O
profiles	O
in	O
NOA	O
testes	O
to	O
those	O
of	O
OA	O
testes	O
using	O
the	O
Agilent	O
Human	B-OG
1A	O
(	O
v2	O
)	O
Oligo	O
Microarray	O
system	O
.	O

We	O
chose	O
the	O
‘	O
standard	O
reference	O
design	O
'	O
in	O
two	O
-	O
color	O
microarray	O
experiments	O
as	O
an	O
experimental	O
design	O
for	O
the	O
expression	O
analysis	O
[	O
8	O
],	O
where	O
a	O
single	O
microarray	O
was	O
used	O
to	O
compare	O
either	O
NOA	O
or	O
OA	O
to	O
the	O
testicular	O
reference	O
RNA	O
as	O
described	O
in	O
Materials	O
and	O
Methods	O
(	O
Figure	O
1B	O
).	O

Experimental	O
Design	O
to	O
Extract	O
NOA	O
-	O
related	O
Target	O
Genes	O

(	O
A	O
)	O
Representative	O
testicular	O
biopsies	O
from	O
NOA	O
(	O
left	O
panel	O
)	O
and	O
OA	O
(	O
right	O
panel	O
)	O
patients	O
.	O

The	O
seminiferous	O
tubules	O
in	O
NOA	O
testis	O
show	O
Sertoli	O
cells	O
only	O
;	O
testicular	O
histology	O
of	O
the	O
OA	O
patient	O
indicates	O
the	O
presence	O
of	O
germ	O
cells	O
at	O
all	O
stages	O
of	O
spermatogenesis	O
.	O

(	O
B	O
)	O
Strategy	O
for	O
discovering	O
the	O
NOA	O
-	O
specific	O
expression	O
profile	O
,	O
i	O
.	O
e	O
.,	O
the	O
NOA	O
-	O
related	O
target	O
genes	O
.	O

Compared	O
with	O
the	O
expression	O
level	O
of	O
reference	O
RNA	O
,	O
the	O
NOA	O
group	O
,	O
with	O
expression	O
undergoing	O
2	O
-	O
fold	O
or	O
more	O
mean	O
change	O
,	O
was	O
extracted	O
;	O
the	O
OA	O
group	O
comprised	O
transcripts	O
with	O
less	O
than	O
2	O
-	O
fold	O
mean	O
expression	O
change	O
.	O

Of	O
the	O
overlapping	O
transcripts	O
,	O
only	O
those	O
with	O
statistically	O
significant	O
difference	O
between	O
NOA	O
and	O
OA	O
(	O
p	O
<	O
0	O
.	O
05	O
with	O
Bonferroni	O
'	O
s	O
correction	O
)	O
were	O
identified	O
as	O
differentially	O
expressed	O
.	O

Of	O
the	O
18	O
,	O
716	O
transcripts	O
screened	O
with	O
the	O
microarray	O
,	O
we	O
obtained	O
transcripts	O
that	O
showed	O
a	O
2	O
-	O
fold	O
mean	O
expression	O
difference	O
between	O
NOA	O
and	O
the	O
reference	O
,	O
the	O
NOA	O
group	O
;	O
the	O
OA	O
group	O
comprised	O
transcripts	O
showing	O
less	O
than	O
2	O
-	O
fold	O
mean	O
expression	O
difference	O
between	O
OA	O
and	O
the	O
reference	O
(	O
Figure	O
1B	O
).	O

Of	O
the	O
transcripts	O
overlapping	O
the	O
two	O
groups	O
,	O
2	O
,	O
611	O
transcripts	O
were	O
found	O
to	O
be	O
differentially	O
expressed	O
between	O
NOA	O
and	O
OA	O
testes	O
after	O
statistical	O
filtering	O
(	O
based	O
on	O
lowess	O
-	O
normalized	O
natural	O
log	O
[	O
Cy5	O
/	O
Cy3	O
],	O
Bonferroni	O
'	O
s	O
corrected	O
p	O
<	O
0	O
.	O
05	O
).	O

This	O
gene	O
list	O
,	O
termed	O
NOA	O
-	O
related	O
target	O
genes	O
,	O
comprised	O
902	O
elevated	O
and	O
1	O
,	O
709	O
decreased	O
transcripts	O
in	O
NOA	O
testes	O
.	O

To	O
characterize	O
the	O
gene	O
list	O
from	O
the	O
biological	O
aspect	O
,	O
the	O
2	O
,	O
611	O
transcripts	O
were	O
subjected	O
to	O
functional	O
clustering	O
according	O
to	O
Gene	O
Ontology	O
(	O
GO	O
)	O
classification	O
for	O
biological	O
processes	O
with	O
GeneSpring	O
software	O
.	O

We	O
identified	O
a	O
total	O
of	O
190	O
GO	O
categories	O
that	O
were	O
significantly	O
(	O
p	O
<	O
0	O
.	O
05	O
without	O
multiple	O
testing	O
correction	O
)	O
over	O
-	O
represented	O
among	O
the	O
2	O
,	O
611	O
transcripts	O
.	O
Table	O
1	O
shows	O
the	O
ten	O
top	O
-	O
ranked	O
GO	O
categories	O
in	O
descending	O
order	O
of	O
significance	O
based	O
on	O
p	O
-	O
values	O
with	O
Fisher	O
'	O
s	O
exact	O
test	O
.	O

It	O
is	O
notable	O
that	O
the	O
GO	O
categories	O
involved	O
in	O
gametogenesis	O
(	O
GO	O
:	O
48232	O
;	O
7283	O
;	O
7276	O
),	O
reproduction	O
(	O
GO	O
:	O
19953	O
;	O
3	O
),	O
and	O
the	O
cell	O
cycle	O
(	O
GO	O
:	O
279	O
;	O
51301	O
;	O
7049	O
;	O
7067	O
)	O
are	O
significantly	O
associated	O
with	O
the	O
gene	O
list	O
.	O

We	O
further	O
analyzed	O
two	O
separate	O
subsets	O
comprising	O
1	O
,	O
709	O
decreased	O
(	O
Figure	O
2	O
,	O
upper	O
)	O
and	O
902	O
elevated	O
(	O
Figure	O
2	O
,	O
lower	O
)	O
transcripts	O
,	O
based	O
on	O
their	O
GO	O
annotations	O
.	O

The	O
top	O
-	O
ranked	O
GO	O
categories	O
for	O
NOA	O
-	O
related	O
target	O
genes	O
are	O
more	O
similar	O
to	O
those	O
of	O
the	O
1	O
,	O
709	O
decreased	O
transcripts	O
than	O
to	O
those	O
of	O
the	O
902	O
elevated	O
ones	O
(	O
Figure	O
2	O
;	O
Table	O
1	O
).	O

Thus	O
,	O
the	O
predominant	O
features	O
may	O
reflect	O
spermatogenic	O
defects	O
common	O
to	O
NOA	O
testes	O
.	O

On	O
the	O
other	O
hand	O
,	O
902	O
transcripts	O
elevated	O
in	O
NOA	O
testes	O
exhibited	O
a	O
distinct	O
GO	O
profile	O
that	O
included	O
several	O
GO	O
categories	O
involved	O
in	O
biosynthesis	O
and	O
metabolism	O
in	O
cytoplasm	O
(	O
Figure	O
2	O
),	O
implying	O
an	O
increase	O
in	O
cytoplasmic	O
turnover	O
rates	O
such	O
as	O
steroid	O
turnover	O
in	O
NOA	O
testes	O
.	O

Top	O
-	O
Ranked	O
Ten	O
Categories	O
of	O
Gene	O
Ontology	O
Significantly	O
Overrepresented	O
among	O
2	O
,	O
611	O
Transcripts	O

Comparison	O
of	O
Ten	O
Top	O
-	O
ranked	O
Gene	O
Ontology	O
(	O
GO	O
)	O
Categories	O
Significantly	O
Over	O
-	O
Represented	O
in	O
the	O
Two	O
Subsets	O
(	O
1	O
,	O
709	O
Decreased	O
,	O
Upper	O
Panel	O
;	O
903	O
Elevated	O
,	O
Lower	O
Panel	O
)	O
of	O
NOA	O
-	O
related	O
Target	O
Genes	O

Blue	O
and	O
red	O
bars	O
represent	O
p	O
-	O
values	O
for	O
the	O
ten	O
top	O
-	O
ranked	O
GO	O
categories	O
over	O
-	O
represented	O
in	O
the	O
decreased	O
and	O
elevated	O
gene	O
lists	O
,	O
respectively	O
.	O

Black	O
bars	O
show	O
the	O
corresponding	O
p	O
-	O
value	O
using	O
2	O
,	O
611	O
NOA	O
-	O
related	O
target	O
genes	O
.	O
p	O
-	O
Values	O
were	O
determined	O
by	O
Fisher	O
'	O
s	O
exact	O
test	O
using	O
all	O
of	O
the	O
GO	O
-	O
annotated	O
genes	O
on	O
the	O
Agilent	O
Human	B-OG
1A	O
(	O
v2	O
)	O
microarray	O
as	O
a	O
background	O
,	O
as	O
shown	O
in	O
Table	O
1	O
.	O

The	O
p	O
-	O
values	O
are	O
expressed	O
as	O
the	O
negative	O
logarithm	O
(	O
base	O
10	O
).	O

Discovery	O
of	O
Three	O
Molecular	O
Subclasses	O
of	O
NOA	O
Testes	O

To	O
clarify	O
heterogeneity	O
of	O
NOA	O
testes	O
at	O
the	O
transcriptome	O
level	O
,	O
we	O
further	O
examined	O
NOA	O
-	O
related	O
target	O
genes	O
to	O
identify	O
NOA	O
subclasses	O
without	O
prior	O
classification	O
with	O
pathological	O
features	O
.	O

We	O
adopted	O
the	O
NMF	O
algorithm	O
coupled	O
with	O
a	O
model	O
selection	O
method	O
[	O
6	O
]	O
to	O
a	O
complete	O
dataset	O
of	O
945	O
out	O
of	O
the	O
2	O
,	O
611	O
transcripts	O
without	O
missing	O
values	O
of	O
signal	O
intensities	O
for	O
a	O
total	O
of	O
47	O
NOA	O
samples	O
.	O
Figure	O
3A	O
shows	O
reordered	O
consensus	O
matrices	O
averaging	O
50	O
connective	O
matrices	O
generated	O
for	O
subclasses	O
K	O
=	O
2	O
,	O
3	O
,	O
4	O
,	O
and	O
5	O
.	O

Distinct	O
patterns	O
of	O
block	O
partitioning	O
were	O
observed	O
at	O
models	O
with	O
2	O
and	O
3	O
subclasses	O
(	O
K	O
=	O
2	O
and	O
3	O
),	O
whereas	O
higher	O
ranks	O
(	O
K	O
=	O
4	O
and	O
5	O
)	O
made	O
block	O
partitioning	O
indistinct	O
.	O

Thus	O
,	O
the	O
NMF	O
method	O
predicts	O
the	O
existence	O
of	O
reproducible	O
and	O
robust	O
subclasses	O
of	O
NOA	O
samples	O
for	O
K	O
=	O
2	O
and	O
3	O
.	O

This	O
prediction	O
was	O
quantitatively	O
supported	O
by	O
higher	O
values	O
of	O
cophenetic	O
correlation	O
coefficients	O
(	O
coph	O
)	O
for	O
NMF	O
-	O
clustered	O
matrices	O
.	O

The	O
NMF	O
class	O
assignment	O
for	O
K	O
=	O
3	O
showed	O
the	O
highest	O
coph	O
value	O
(	O
coph	O
=	O
0	O
.	O
993	O
),	O
indicating	O
that	O
three	O
molecular	O
subclasses	O
,	O
termed	O
NOA1	O
,	O
NOA2	O
,	O
and	O
NOA3	O
,	O
are	O
the	O
most	O
reasonable	O
subclassification	O
among	O
47	O
NOA	O
samples	O
.	O

For	O
comparative	O
analysis	O
of	O
class	O
discovery	O
,	O
a	O
hierarchical	O
clustering	O
(	O
HC	O
)	O
approach	O
was	O
applied	O
to	O
log	O
-	O
transformed	O
normalized	O
ratios	O
for	O
NOA	O
-	O
related	O
target	O
genes	O
.	O

As	O
shown	O
in	O
Figure	O
3B	O
,	O
the	O
HC	O
dendrogram	O
exhibited	O
a	O
clustering	O
pattern	O
similar	O
to	O
that	O
of	O
the	O
NMF	O
-	O
based	O
subclassification	O
,	O
as	O
the	O
three	O
NMF	O
-	O
subclasses	O
of	O
NOA	O
samples	O
tended	O
to	O
form	O
distinct	O
clusters	O
in	O
the	O
HC	O
analysis	O
.	O

Thus	O
,	O
the	O
HC	O
clustering	O
for	O
NOA	O
-	O
related	O
target	O
genes	O
appears	O
to	O
justify	O
the	O
three	O
NMF	O
-	O
based	O
subclasses	O
of	O
NOA	O
samples	O
.	O

Non	O
-	O
Negative	O
Matrix	O
Factorization	O
(	O
NMF	O
)	O
and	O
Hierarchical	O
Clustering	O
(	O
HC	O
)-	O
based	O
Subclassification	O
of	O
47	O
NOA	O
Samples	O

(	O
A	O
)	O
Reordered	O
consensus	O
matrices	O
averaging	O
50	O
connectivity	O
matrices	O
computed	O
at	O
K	O
=	O
2	O
–	O
5	O
(	O
as	O
the	O
number	O
of	O
subclasses	O
modeled	O
)	O
for	O
the	O
NOA	O
data	O
set	O
comprising	O
of	O
NOA	O
-	O
related	O
target	O
genes	O
.	O

NMF	O
computation	O
and	O
model	O
selection	O
were	O
performed	O
according	O
to	O
Brunet	O
et	O
al	O
.	O
[	O
6	O
]	O
as	O
described	O
in	O
Materials	O
and	O
Methods	O
.	O

According	O
to	O
cophenetic	O
correlation	O
coefficients	O
(	O
coph	O
)	O
for	O
NMF	O
-	O
clustered	O
matrices	O
,	O
the	O
NMF	O
class	O
assignment	O
for	O
K	O
=	O
3	O
was	O
the	O
most	O
robust	O
.	O

(	O
B	O
)	O
The	O
HC	O
method	O
incorporated	O
in	O
GeneSpring	O
also	O
was	O
used	O
to	O
classify	O
NOA	O
heterogeneity	O
in	O
testicular	O
gene	O
expression	O
.	O

To	O
display	O
correspondences	O
of	O
subclassification	O
by	O
the	O
two	O
methods	O
,	O
the	O
NMF	O
class	O
assignments	O
for	O
K	O
=	O
3	O
are	O
shown	O
color	O
-	O
coded	O
;	O
NOA1	O
(	O
green	O
),	O
NOA2	O
(	O
pink	O
),	O
and	O
NOA3	O
(	O
light	O
purple	O
).	O

To	O
investigate	O
the	O
clinical	O
features	O
of	O
the	O
three	O
NOA	O
subclasses	O
,	O
we	O
compared	O
several	O
clinical	O
measures	O
among	O
the	O
subclasses	O
.	O

The	O
results	O
obtained	O
from	O
statistical	O
analyses	O
in	O
a	O
total	O
of	O
four	O
groups	O
including	O
the	O
OA	O
group	O
are	O
summarized	O
in	O
Table	O
2	O
.	O

We	O
found	O
significant	O
differences	O
in	O
the	O
three	O
NOA	O
-	O
related	O
clinical	O
characteristics	O
,	O
testicular	O
histological	O
score	O
(	O
Johnsen	O
'	O
s	O
score	O
,	O
p	O
=	O
1	O
.	O
4	O
×	O
10	O
−	O
6	O
),	O
serum	O
FSH	B-GP
level	O
(	O
p	O
=	O
9	O
.	O
8	O
×	O
10	O
−	O
4	O
),	O
and	O
LH	B-GP
level	O
(	O
p	O
=	O
0	O
.	O
0051	O
)	O
among	O
the	O
four	O
groups	O
using	O
Kruskal	O
-	O
Wallis	O
test	O
,	O
but	O
there	O
were	O
no	O
differences	O
in	O
age	O
and	O
serum	O
testosterone	O
level	O
.	O
Post	O
hoc	O
pairwise	O
comparisons	O
revealed	O
that	O
both	O
the	O
NOA1	O
and	O
NOA2	O
groups	O
exhibited	O
low	O
Johnsen	O
'	O
s	O
scores	O
and	O
high	O
levels	O
of	O
serum	O
FSH	B-GP
compared	O
with	O
the	O
OA	O
group	O
(	O
Table	O
2	O
).	O

In	O
the	O
NOA1	O
group	O
,	O
a	O
high	O
LH	B-GP
level	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
also	O
was	O
found	O
compared	O
with	O
the	O
OA	O
group	O
.	O

On	O
the	O
other	O
hand	O
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
any	O
of	O
the	O
parameters	O
between	O
the	O
NOA3	O
and	O
OA	O
groups	O
,	O
as	O
well	O
as	O
among	O
three	O
NOA	O
subclasses	O
in	O
post	O
hoc	O
analysis	O
.	O

Elevations	O
of	O
serum	O
FSH	B-GP
and	O
LH	B-GP
concentrations	O
often	O
are	O
observed	O
in	O
infertile	B-DS
patients	O
with	O
abnormal	O
testicular	O
histologies	O
and	O
are	O
correlated	O
,	O
to	O
some	O
extent	O
,	O
with	O
the	O
severity	O
of	O
spermatogenic	O
defects	O
[	O
9	O
,	O
10	O
].	O

Testicular	O
histologies	O
of	O
NOA	O
and	O
OA	O
patients	O
have	O
been	O
evaluated	O
by	O
the	O
Johnsen	O
'	O
s	O
scores	O
,	O
ranging	O
from	O
10	O
to	O
1	O
according	O
to	O
the	O
presence	O
or	O
absence	O
of	O
spermatogenesis	O
-	O
related	O
cell	O
types	O
(	O
spermatozoa	O
,	O
spermatids	O
,	O
spermatocytes	O
,	O
spermatogonia	O
,	O
and	O
Sertoli	O
cells	O
)	O
in	O
seminiferous	O
tubules	O
[	O
11	O
].	O

The	O
NMF	O
-	O
based	O
subclasses	O
of	O
testicular	O
gene	O
expression	O
showed	O
that	O
the	O
low	O
score	O
classes	O
had	O
heterogeneity	O
(	O
NOA1	O
and	O
NOA2	O
),	O
presumably	O
indicating	O
the	O
possibility	O
of	O
distinct	O
spermatogenic	O
defects	O
at	O
the	O
molecular	O
level	O
that	O
could	O
not	O
be	O
detected	O
by	O
morphological	O
examination	O
.	O

Clinical	O
Characteristics	O
of	O
Three	O
Molecular	O
Subclasses	O
of	O
NOA	O

Identification	O
of	O
Transcripts	O
Differentially	O
Expressed	O
in	O
the	O
Three	O
NOA	O
Subclasses	O

Based	O
on	O
the	O
three	O
NOA	O
subclasses	O
,	O
we	O
conducted	O
further	O
statistical	O
analyses	O
to	O
extract	O
transcripts	O
representing	O
expression	O
differences	O
between	O
NOA	O
subclasses	O
from	O
the	O
NOA	O
-	O
related	O
target	O
genes	O
(	O
Figure	O
S1	O
).	O

149	O
out	O
of	O
2	O
,	O
611	O
transcripts	O
showed	O
significant	O
differences	O
(	O
p	O
<	O
0	O
.	O
05	O
,	O
Tukey	O
'	O
s	O
post	O
hoc	O
test	O
)	O
in	O
testicular	O
expression	O
between	O
the	O
NOA	O
subclasses	O
,	O
as	O
summarized	O
in	O
Table	O
S1	O
.	O

To	O
characterize	O
this	O
gene	O
list	O
based	O
on	O
GO	O
classification	O
for	O
biological	O
processes	O
,	O
we	O
examined	O
which	O
GO	O
terms	O
were	O
highly	O
associated	O
with	O
the	O
149	O
differentially	O
expressed	O
transcripts	O
,	O
relative	O
to	O
those	O
for	O
the	O
NOA	O
-	O
related	O
gene	O
list	O
(	O
as	O
shown	O
in	O
Table	O
1	O
and	O
Figure	O
2	O
).	O
Figure	O
4	O
shows	O
the	O
10	O
top	O
-	O
ranked	O
GO	O
categories	O
for	O
the	O
149	O
transcripts	O
,	O
using	O
the	O
2	O
,	O
611	O
NOA	O
-	O
related	O
target	O
transcripts	O
as	O
a	O
background	O
set	O
of	O
genes	O
for	O
this	O
GO	O
analysis	O
.	O

Nine	O
GO	O
categories	O
excluding	O
gametogenesis	O
appeared	O
to	O
be	O
novel	O
,	O
indicating	O
that	O
highly	O
significant	O
enrichments	O
of	O
transcripts	O
involved	O
in	O
DNA	O
metabolism	O
(	O
GO	O
:	O
6259	O
;	O
6325	O
;	O
6323	O
;	O
6281	O
),	O
chromosome	O
organization	O
and	O
biogenesis	O
(	O
GO	O
:	O
51276	O
;	O
7001	O
),	O
sex	O
differentiation	O
(	O
GO	O
:	O
7548	O
),	O
and	O
response	O
to	O
endogenous	O
stimulus	O
(	O
GO	O
:	O
9719	O
;	O
6974	O
)	O
occurred	O
after	O
the	O
extraction	O
of	O
149	O
transcripts	O
from	O
the	O
NOA	O
-	O
related	O
target	O
gene	O
list	O
(	O
Figure	O
4	O
).	O

Other	O
features	O
of	O
the	O
149	O
transcripts	O
from	O
the	O
gene	O
list	O
(	O
Table	O
S1	O
)	O
were	O
as	O
follows	O
:	O
(	O
1	O
)	O
a	O
high	O
frequency	O
(	O
24	O
.	O
2	O
%)	O
of	O
sex	O
chromosome	O
-	O
linked	O
genes	O
;	O
(	O
2	O
)	O
a	O
high	O
frequency	O
(	O
13	O
.	O
4	O
%)	O
of	O
genes	O
encoding	O
cancer	B-DS
/	O
testis	O
antigens	O
[	O
12	O
,	O
13	O
];	O
and	O
(	O
3	O
)	O
a	O
moderate	O
frequency	O
(	O
6	O
.	O
7	O
%)	O
of	O
male	B-DS
infertility	I-DS
-	O
related	O
genes	O
.	O

Defect	O
of	O
these	O
genes	O
results	O
in	O
male	B-DS
infertility	I-DS
/	O
subfertility	B-DS
in	O
mice	B-OG
[	O
3	O
,	O
14	O
–	O
16	O
].	O

Significant	O
Enrichments	O
of	O
Gene	O
Ontology	O
Categories	O
in	O
GO	O
-	O
based	O
Profiling	O
of	O
149	O
Differentially	O
Expressed	O
Transcripts	O

Grey	O
bars	O
represent	O
p	O
-	O
values	O
(	O
expressed	O
as	O
the	O
negative	O
logarithm	O
[	O
base	O
10	O
])	O
for	O
the	O
10	O
top	O
-	O
ranked	O
GO	O
categories	O
over	O
-	O
represented	O
in	O
the	O
149	O
differentially	O
expressed	O
transcripts	O
,	O
using	O
the	O
2	O
,	O
611	O
NOA	O
-	O
related	O
target	O
transcripts	O
as	O
a	O
background	O
set	O
of	O
genes	O
for	O
the	O
determination	O
of	O
p	O
-	O
values	O
.	O

The	O
actual	O
number	O
of	O
differentially	O
expressed	O
transcripts	O
involved	O
in	O
each	O
category	O
is	O
given	O
in	O
parentheses	O
.	O

In	O
the	O
process	O
of	O
extracting	O
the	O
149	O
transcripts	O
from	O
the	O
NOA	O
-	O
related	O
target	O
gene	O
list	O
,	O
sets	O
of	O
genes	O
involved	O
in	O
nine	O
GO	O
categories	O
,	O
marked	O
in	O
magenta	O
,	O
were	O
more	O
condensed	O
because	O
they	O
were	O
not	O
found	O
in	O
the	O
previous	O
10	O
top	O
-	O
ranked	O
GO	O
lists	O
of	O
NOA	O
-	O
related	O
target	O
genes	O
(	O
see	O
Table	O
1	O
and	O
Figure	O
2	O
).	O

Twenty	O
-	O
five	O
of	O
the	O
149	O
transcripts	O
showing	O
differences	O
in	O
between	O
-	O
subclass	O
expression	O
displayed	O
elevated	O
expression	O
in	O
NOA	O
,	O
while	O
the	O
others	O
(	O
124	O
transcripts	O
)	O
had	O
decreased	O
expression	O
(	O
Table	O
S1	O
).	O

The	O
25	O
NOA	O
-	O
elevated	O
transcripts	O
accounted	O
only	O
for	O
differences	O
in	O
testicular	O
expression	O
between	O
NOA1	O
and	O
the	O
other	O
two	O
subclasses	O
,	O
NOA2	O
and	O
NOA3	O
(	O
Figure	O
S2	O
;	O
Table	O
S1	O
),	O
suggesting	O
testicular	O
hyperactivity	O
in	O
NOA1	O
patients	O
.	O

For	O
example	O
,	O
3β	B-GP
-	I-GP
hydroxysteroid	I-GP
dehydrogenase	I-GP
,	O
encoded	O
by	O
HSD3B2	B-GP
and	O
HSD3B1	B-GP
,	O
plays	O
a	O
crucial	O
role	O
in	O
biosynthesis	O
of	O
testosterone	O
in	O
Leydig	O
cells	O
[	O
17	O
].	O

Expression	O
levels	O
of	O
the	O
two	O
transcripts	O
in	O
the	O
NOA1	O
subclass	O
were	O
higher	O
than	O
those	O
in	O
the	O
NOA2	O
and	O
NOA3	O
subclasses	O
,	O
and	O
the	O
expression	O
difference	O
between	O
NOA1	O
and	O
NOA3	O
was	O
significant	O
by	O
Tukey	O
'	O
s	O
post	O
hoc	O
test	O
(	O
Figure	O
S2	O
;	O
Table	O
S1	O
).	O

As	O
the	O
NOA1	O
subclass	O
showed	O
significantly	O
high	O
LH	B-GP
and	O
slightly	O
low	O
testosterone	O
levels	O
(	O
Table	O
2	O
),	O
the	O
elevated	O
levels	O
of	O
the	O
two	O
transcripts	O
may	O
be	O
explained	O
by	O
a	O
compensation	O
process	O
for	O
maintaining	O
normal	O
testosterone	O
level	O
.	O

Thus	O
,	O
such	O
enhanced	O
steroidogenesis	O
of	O
the	O
NOA1	O
subclass	O
might	O
favor	O
,	O
even	O
if	O
only	O
slightly	O
,	O
testicular	O
hyperactivity	O
in	O
NOA1	O
patients	O
.	O

On	O
the	O
other	O
hand	O
,	O
among	O
the	O
124	O
NOA	O
-	O
decreased	O
transcripts	O
,	O
most	O
transcripts	O
(	O
118	O
/	O
124	O
)	O
showed	O
expression	O
differences	O
between	O
NOA3	O
and	O
the	O
other	O
two	O
subclasses	O
(	O
Figures	O
S2	O
–	O
S4	O
;	O
Table	O
S1	O
).	O

Expression	O
levels	O
of	O
these	O
transcripts	O
in	O
the	O
NOA3	O
subclass	O
were	O
similar	O
to	O
those	O
in	O
testis	O
reference	O
RNA	O
(	O
Figures	O
S2	O
–	O
S4	O
),	O
indicating	O
that	O
the	O
NOA3	O
subclass	O
has	O
a	O
mild	O
defect	O
in	O
spermatogenesis	O
.	O

This	O
notion	O
is	O
supported	O
by	O
the	O
fact	O
that	O
the	O
expression	O
of	O
INHBB	B-GP
encoding	O
inhibin	B-GP
β	I-GP
subunit	I-GP
B	I-GP
in	O
the	O
NOA3	O
subclass	O
is	O
normal	O
while	O
NOA1	O
and	O
NOA2	O
subclasses	O
showed	O
low	O
levels	O
,	O
indicating	O
that	O
inhibin	B-GP
β	I-GP
may	O
be	O
a	O
marker	O
of	O
testicular	O
dysfunction	O
,	O
as	O
previously	O
reported	O
[	O
18	O
].	O

Verification	O
of	O
Between	O
-	O
Subclass	O
Differences	O
in	O
Testicular	O
Expression	O
by	O
Quantitative	O
Real	O
-	O
Time	O
RT	O
-	O
PCR	O

To	O
evaluate	O
the	O
appropriateness	O
of	O
microarray	O
data	O
on	O
transcripts	O
representing	O
expression	O
differences	O
between	O
NOA	O
subclasses	O
,	O
we	O
selected	O
53	O
with	O
high	O
significance	O
(	O
p	O
<	O
0	O
.	O
01	O
,	O
Tukey	O
'	O
s	O
post	O
hoc	O
test	O
,	O
Figure	O
S1	O
and	O
Table	O
S1	O
)	O
out	O
of	O
the	O
149	O
differentially	O
expressed	O
transcripts	O
and	O
subjected	O
them	O
to	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
analysis	O
.	O

Of	O
the	O
53	O
transcripts	O
,	O
the	O
highly	O
homologous	O
VCX	B-GP
family	O
genes	O
,	O
VCX	B-GP
,	O
VCX2	B-GP
,	O
and	O
VCX3A	B-GP
,	O
were	O
detected	O
with	O
non	O
-	O
specific	O
assay	O
as	O
a	O
mixture	O
of	O
transcripts	O
.	O

Thus	O
,	O
50	O
genes	O
and	O
one	O
gene	O
mixture	O
were	O
subjected	O
to	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
.	O

As	O
shown	O
in	O
Figure	O
S5	O
,	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
data	O
of	O
the	O
51	O
transcripts	O
were	O
highly	O
correlated	O
with	O
the	O
results	O
of	O
microarray	O
analysis	O
,	O
the	O
squares	O
of	O
correlation	O
coefficients	O
(	O
R	O
2	O
)	O
ranging	O
from	O
0	O
.	O
40	O
(	O
CT45	O
–	O
2	O
)	O
to	O
0	O
.	O
90	O
(	O
GAJ	O
).	O

This	O
validation	O
analysis	O
also	O
provided	O
statistically	O
positive	O
evidence	O
on	O
between	O
-	O
subclass	O
differences	O
for	O
all	O
of	O
the	O
51	O
transcripts	O
(	O
p	O
<	O
0	O
.	O
05	O
with	O
Kruskal	O
-	O
Wallis	O
test	O
,	O
data	O
not	O
shown	O
).	O

Screening	O
of	O
Candidate	O
Genes	O
for	O
Genetic	O
Susceptibility	O
for	O
NOA	O

One	O
approach	O
to	O
prioritizing	O
candidate	O
genes	O
for	O
genetic	O
susceptibility	O
underlying	O
NOA	O
is	O
to	O
adopt	O
gene	O
expression	O
data	O
from	O
NOA	O
tissues	O
.	O

Genes	O
that	O
show	O
differences	O
in	O
expression	O
level	O
between	O
NOA	O
subclasses	O
regardless	O
of	O
biological	O
impact	O
were	O
selected	O
based	O
on	O
the	O
concept	O
that	O
polymorphic	O
variation	O
in	O
gene	O
expression	O
among	O
unrelated	O
individuals	O
is	O
largely	O
due	O
to	O
polymorphisms	O
in	O
DNA	O
sequence	O
[	O
19	O
,	O
20	O
].	O

52	O
genes	O
having	O
statistical	O
differences	O
in	O
expression	O
(	O
p	O
<	O
0	O
.	O
01	O
,	O
Table	O
S1	O
)	O
were	O
regarded	O
as	O
candidates	O
for	O
allelic	O
association	O
with	O
NOA	O
.	O

Despite	O
the	O
fact	O
that	O
these	O
genes	O
were	O
not	O
selected	O
based	O
on	O
pathological	O
relevance	O
to	O
NOA	O
,	O
genes	O
such	O
as	O
SYCP3	B-GP
,	O
DAZL	B-GP
,	O
and	O
INHBB	B-GP
,	O
which	O
were	O
reported	O
to	O
function	O
in	O
spermatogenesis	O
were	O
included	O
[	O
21	O
–	O
23	O
].	O

191	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
of	O
42	O
genes	O
were	O
subjected	O
to	O
allelic	O
association	O
study	O
with	O
190	O
NOA	O
patients	O
and	O
190	O
fertile	O
men	O
in	O
the	O
first	O
round	O
of	O
screening	O
.	O

Ten	O
genes	O
(	O
CTAG1B	B-GP
,	O
LOC158812	O
,	O
LOC255313	O
,	O
MAGEA2	B-GP
,	O
PEPP	B-GP
-	I-GP
2	I-GP
,	O
TSPY1	B-GP
,	O
TSPY2	B-GP
,	O
VCX3A	B-GP
,	O
VCY	B-GP
,	O
and	O
XAGE1	B-GP
)	O
were	O
not	O
analyzed	O
because	O
no	O
gene	O
-	O
based	O
SNPs	O
with	O
minor	O
allele	O
frequency	O
(	O
MAF	O
)	O
>	O
0	O
.	O
05	O
could	O
be	O
found	O
.	O

We	O
identified	O
seven	O
genes	O
(	O
ART3	B-GP
,	O
LOC92196	O
,	O
NYD	B-GP
-	I-GP
SP20	I-GP
,	O
PAGE5	B-GP
,	O
TEX14	B-GP
,	O
TKTL1	B-GP
,	O
and	O
XAGE5	B-GP
)	O
with	O
at	O
least	O
one	O
SNP	O
showing	O
a	O
discrepancy	O
in	O
MAF	O
of	O
5	O
%	O
or	O
greater	O
between	O
cases	O
and	O
controls	O
(	O
Table	O
S2	O
).	O

Forty	O
-	O
four	O
SNPs	O
in	O
the	O
seven	O
genes	O
were	O
subjected	O
to	O
a	O
second	O
round	O
of	O
screening	O
by	O
increasing	O
sample	O
size	O
(	O
380	O
NOA	O
patients	O
and	O
380	O
fertile	O
men	O
).	O

After	O
the	O
two	O
rounds	O
of	O
screenings	O
,	O
only	O
one	O
SNP	O
(	O
rs6836703	O
)	O
of	O
ART3	B-GP
(	O
ADP	B-GP
-	I-GP
ribosyltransferase	I-GP
3	I-GP
)	O
was	O
positively	O
associated	O
with	O
NOA	O
after	O
Bonferroni	O
'	O
s	O
correction	O
for	O
multiple	O
testing	O
(	O
Table	O
3	O
;	O
χ2	O
=	O
11	O
.	O
7	O
,	O
corrected	O
p	O
=	O
0	O
.	O
027	O
).	O

Analyses	O
of	O
Allelic	O
Association	O
between	O
44	O
SNPs	O
of	O
Seven	O
Candidate	O
Genes	O
and	O
Japanese	O
NOA	O
in	O
Second	O
Round	O
of	O
Initial	O
Screening	O
(	O
380	O
Cases	O
versus	O
380	O
Controls	O
)	O

Allelic	O
Association	O
Study	O
with	O
ART3	B-GP

We	O
focused	O
on	O
ART3	B-GP
based	O
on	O
the	O
result	O
of	O
the	O
two	O
rounds	O
of	O
screenings	O
,	O
and	O
identified	O
38	O
SNPs	O
with	O
MAF	O
>	O
0	O
.	O
1	O
by	O
database	O
search	O
or	O
direct	O
sequencing	O
of	O
the	O
gene	O
.	O

442	O
NOA	O
patients	O
(	O
cases	O
)	O
and	O
475	O
fertile	O
men	O
(	O
controls	O
)	O
were	O
genotyped	O
.	O

Because	O
we	O
intended	O
in	O
this	O
study	O
to	O
find	O
a	O
common	O
genetic	O
cause	O
for	O
NOA	O
,	O
patients	O
with	O
microdeletions	O
of	O
the	O
Y	O
chromosome	O
at	O
the	O
azoospermia	B-GP
factor	I-GP
(	O
AZF	B-GP
)	O
locus	O
,	O
one	O
of	O
the	O
major	O
causes	O
of	O
NOA	O
[	O
1	O
,	O
2	O
],	O
were	O
not	O
excluded	O
from	O
the	O
cases	O
.	O

However	O
,	O
to	O
characterize	O
the	O
cases	O
in	O
regard	O
to	O
the	O
AZF	B-GP
deletions	O
,	O
we	O
examined	O
the	O
incidence	O
of	O
the	O
deletions	O
in	O
a	O
subset	O
of	O
the	O
cases	O
.	O

Of	O
the	O
442	O
NOA	O
patients	O
,	O
99	O
were	O
examined	O
by	O
PCR	O
-	O
based	O
screening	O
.	O

Fourteen	O
(	O
14	O
.	O
1	O
%)	O
of	O
the	O
99	O
cases	O
examined	O
showed	O
the	O
AZF	B-GP
deletions	O
,	O
and	O
NOA	O
patients	O
with	O
AZFc	O
deletions	O
were	O
most	O
frequent	O
among	O
the	O
14	O
cases	O
(	O
data	O
not	O
shown	O
).	O

The	O
overall	O
deletion	O
frequency	O
was	O
comparable	O
to	O
those	O
of	O
other	O
studies	O
[	O
1	O
,	O
2	O
],	O
in	O
which	O
the	O
higher	O
incidence	O
of	O
AZFc	O
deletions	O
also	O
was	O
observed	O
.	O

The	O
clinical	O
characteristics	O
of	O
patients	O
with	O
the	O
AZF	B-GP
deletions	O
did	O
not	O
differ	O
from	O
those	O
of	O
the	O
other	O
NOA	O
patients	O
(	O
data	O
not	O
shown	O
).	O

Linkage	O
disequilibrium	O
map	O
showed	O
that	O
all	O
of	O
the	O
SNPs	O
of	O
ART3	B-GP
were	O
in	O
near	O
complete	O
LD	O
evaluated	O
with	O
D	O
'	O
statistic	O
(|	O
D	O
'|	O
>	O
0	O
.	O
7	O
)	O
in	O
both	O
cases	O
and	O
controls	O
(	O
only	O
controls	O
are	O
displayed	O
in	O
Figure	O
5	O
).	O

None	O
of	O
the	O
SNPs	O
in	O
the	O
controls	O
showed	O
deviation	O
from	O
Hardy	O
-	O
Weinberg	O
'	O
s	O
equilibrium	O
at	O
a	O
threshold	O
of	O
p	O
<	O
0	O
.	O
01	O
(	O
data	O
not	O
shown	O
).	O

As	O
shown	O
in	O
Table	O
4	O
,	O
SNPs	O
showing	O
positive	O
associations	O
based	O
on	O
nominal	O
p	O
-	O
values	O
were	O
widely	O
distributed	O
throughout	O
ART3	B-GP
.	O

The	O
most	O
significant	O
association	O
was	O
observed	O
with	O
ART3	B-GP
-	O
SNP25	O
(	O
rs6836703	O
)	O
located	O
in	O
intron	O
11	O
of	O
ART3	B-GP
(	O
χ2	O
=	O
9	O
.	O
16	O
,	O
nominal	O
p	O
=	O
0	O
.	O
0025	O
,	O
odds	O
ratio	O
[	O
95	O
%	O
CI	O
]	O
=	O
1	O
.	O
34	O
[	O
1	O
.	O
11	O
–	O
1	O
.	O
63	O
]).	O

We	O
applied	O
the	O
permutation	O
method	O
for	O
adjustment	O
of	O
multiple	O
testing	O
to	O
avoid	O
a	O
false	O
positive	O
result	O
[	O
24	O
].	O

A	O
total	O
of	O
four	O
SNPs	O
including	O
ART3	B-GP
-	O
SNP25	O
met	O
the	O
empirical	O
significance	O
level	O
of	O
p	O
<	O
0	O
.	O
05	O
(	O
Table	O
4	O
).	O

Linkage	O
Disequilibrium	O
Pattern	O
of	O
ART3	B-GP

The	O
gene	O
structure	O
together	O
with	O
the	O
position	O
of	O
38	O
SNPs	O
is	O
shown	O
.	O

Pairwise	O
LD	O
coefficients	O
,	O
D	O
'	O
and	O
r	O
2	O
,	O
of	O
controls	O
were	O
determined	O
and	O
expressed	O
as	O
a	O
block	O
structure	O
.	O

In	O
the	O
schematic	O
block	O
,	O
red	O
boxes	O
indicate	O
pairwise	O
LD	O
of	O
|	O
D	O
'|	O
>	O
0	O
.	O
9	O
or	O
r	O
2	O
>	O
0	O
.	O
8	O
and	O
pink	O
boxes	O
0	O
.	O
9	O
≥	O
|	O
D	O
'|	O
>	O
0	O
.	O
7	O
or	O
0	O
.	O
8	O
≥	O
r	O
2	O
>	O
0	O
.	O
5	O
.	O

Blank	O
boxes	O
represent	O
|	O
D	O
'|	O
≤	O
0	O
.	O
7	O
or	O
r	O
2	O
≤	O
0	O
.	O
5	O
.	O

Allelic	O
Association	O
of	O
38	O
SNPs	O
in	O
ART3	B-GP
with	O
NOA	O
in	O
Japanese	O
Population	O
(	O
442	O
NOA	O
Patients	O
versus	O
475	O
Controls	O
)	O

Haplotype	O
-	O
based	O
Association	O
Study	O
of	O
ART3	B-GP

The	O
expectation	O
-	O
maximization	O
(	O
EM	O
)	O
algorithm	O
[	O
37	O
]	O
was	O
used	O
to	O
infer	O
ART3	B-GP
haplotype	O
frequencies	O
with	O
genotyping	O
data	O
of	O
five	O
tag	O
SNPs	O
,	O
ART3	B-GP
-	O
SNP1	O
,	O
5	O
,	O
8	O
,	O
23	O
,	O
25	O
,	O
and	O
28	O
(	O
see	O
Table	O
4	O
).	O

At	O
the	O
respective	O
SNP	O
sites	O
,	O
red	O
and	O
blue	O
boxes	O
represent	O
minor	O
and	O
major	O
alleles	O
,	O
respectively	O
.	O

For	O
the	O
haplotype	O
-	O
based	O
association	O
study	O
,	O
we	O
first	O
selected	O
five	O
SNPs	O
(	O
ART3	B-GP
-	O
SNP1	O
,	O
5	O
,	O
23	O
,	O
25	O
,	O
and	O
28	O
)	O
as	O
tag	O
SNPs	O
captured	O
through	O
LD	O
in	O
ART3	B-GP
from	O
15	O
SNPs	O
with	O
nominal	O
p	O
<	O
0	O
.	O
05	O
at	O
a	O
threshold	O
of	O
r	O
2	O
≥	O
0	O
.	O
8	O
with	O
Tagger	O
software	O
[	O
25	O
].	O

Haplotype	O
frequencies	O
were	O
inferred	O
using	O
an	O
expectation	O
-	O
maximization	O
(	O
EM	O
)	O
algorithm	O
.	O

After	O
excluding	O
rare	O
haplotypes	O
(	O
frequency	O
<	O
0	O
.	O
01	O
),	O
association	O
of	O
ART3	B-GP
haplotypes	O
with	O
NOA	O
was	O
examined	O
in	O
442	O
cases	O
and	O
475	O
controls	O
.	O

Haplotype	O
H1	O
,	O
the	O
most	O
common	O
haplotype	O
in	O
controls	O
,	O
was	O
under	O
-	O
represented	O
in	O
cases	O
with	O
significance	O
(	O
Figure	O
6	O
;	O
26	O
.	O
6	O
%	O
in	O
cases	O
and	O
35	O
.	O
3	O
%	O
in	O
controls	O
;	O
χ	O
2	O
=	O
15	O
.	O
7	O
,	O
df	O
=	O
1	O
,	O
nominal	O
p	O
=	O
0	O
.	O
000073	O
),	O
indicating	O
a	O
protective	O
impact	O
of	O
haplotype	O
H1	O
.	O

After	O
Bonferroni	O
'	O
s	O
correction	O
for	O
multiple	O
testing	O
,	O
a	O
protective	O
effect	O
of	O
haplotype	O
H1	O
was	O
still	O
significant	O
(	O
corrected	O
p	O
=	O
0	O
.	O
00080	O
).	O

Other	O
haplotypes	O
showed	O
no	O
significant	O
difference	O
in	O
frequencies	O
between	O
cases	O
and	O
controls	O
(	O
Figure	O
6	O
).	O

We	O
also	O
applied	O
a	O
Bayesian	O
algorithm	O
for	O
phasing	O
haplotypes	O
with	O
PHASE	O
version	O
2	O
.	O
1	O
.	O
1	O
[	O
26	O
,	O
27	O
].	O

Regardless	O
of	O
haplotype	O
-	O
phasing	O
methods	O
,	O
haplotype	O
H1	O
was	O
the	O
most	O
frequent	O
in	O
controls	O
(	O
26	O
.	O
4	O
%	O
in	O
cases	O
and	O
35	O
.	O
0	O
%	O
in	O
controls	O
),	O
and	O
a	O
significant	O
difference	O
in	O
haplotype	O
H1	O
frequency	O
between	O
cases	O
and	O
controls	O
was	O
observed	O
(	O
permutation	O
p	O
<	O
0	O
.	O
0001	O
in	O
global	O
comparison	O
,	O
generated	O
after	O
10	O
,	O
000	O
iterations	O
).	O

Clinical	O
Relevance	O
of	O
the	O
Haplotype	O
Associations	O

The	O
functional	O
relevance	O
of	O
haplotype	O
H1	O
in	O
comparison	O
with	O
the	O
clinical	O
data	O
was	O
then	O
explored	O
.	O

Diplotype	O
was	O
inferred	O
with	O
EM	O
algorithm	O
,	O
and	O
three	O
categories	O
(	O
code	O
0	O
,	O
1	O
,	O
and	O
2	O
)	O
were	O
defined	O
by	O
the	O
number	O
of	O
haplotype	O
H1	O
carried	O
without	O
counting	O
the	O
other	O
haplotypes	O
,	O
and	O
nonparametric	O
analysis	O
of	O
variance	O
test	O
with	O
clinical	O
data	O
was	O
performed	O
.	O

Serum	O
levels	O
of	O
hormones	O
(	O
LH	B-GP
,	O
FSH	B-GP
,	O
and	O
testosterone	O
),	O
other	O
biochemical	O
and	O
pathophysiological	O
markers	O
,	O
and	O
Johnsen	O
'	O
s	O
score	O
were	O
analyzed	O
by	O
Kruskal	O
-	O
Wallis	O
test	O
with	O
a	O
Bonferroni	O
/	O
Dunn	O
post	O
hoc	O
test	O
between	O
the	O
three	O
diplo	O
-	O
groups	O
.	O

Serum	O
testosterone	O
levels	O
were	O
significantly	O
different	O
among	O
the	O
three	O
groups	O
(	O
Figure	O
7	O
;	O
df	O
=	O
2	O
,	O
p	O
=	O
0	O
.	O
0093	O
),	O
but	O
there	O
were	O
no	O
significant	O
differences	O
in	O
other	O
clinical	O
markers	O
.	O
Post	O
hoc	O
pairwise	O
comparisons	O
revealed	O
that	O
serum	O
testosterone	O
levels	O
were	O
significantly	O
higher	O
in	O
the	O
subgroup	O
having	O
two	O
copies	O
of	O
haplotype	O
H1	O
than	O
in	O
a	O
subgroup	O
with	O
one	O
or	O
no	O
haplotype	O
H1	O
(	O
p	O
=	O
0	O
.	O
0064	O
or	O
p	O
=	O
0	O
.	O
0004	O
,	O
respectively	O
,	O
Figure	O
7	O
).	O

PHASE	O
-	O
inferred	O
individual	O
diplotypes	O
also	O
revealed	O
a	O
similar	O
correlation	O
between	O
diplo	O
-	O
groups	O
of	O
haplotype	O
H1	O
and	O
serum	O
testosterone	O
levels	O
(	O
data	O
not	O
shown	O
).	O

Diplotype	O
-	O
Specific	O
Differences	O
in	O
Serum	O
Testosterone	O
Levels	O
in	O
NOA	O
Patients	O

Three	O
diplo	O
-	O
groups	O
(	O
code	O
0	O
,	O
1	O
,	O
and	O
2	O
)	O
were	O
defined	O
by	O
the	O
number	O
of	O
ART3	B-GP
haplotype	O
H1	O
carried	O
.	O

The	O
serum	O
testosterone	O
levels	O
were	O
significantly	O
different	O
among	O
the	O
three	O
groups	O
(	O
Kruskal	O
-	O
Wallis	O
;	O
df	O
=	O
2	O
,	O
p	O
=	O
0	O
.	O
0093	O
)	O
by	O
Bonferroni	O
/	O
Dunn	O
post	O
hoc	O
test	O
.	O

ART3	B-GP
Protein	O
Localization	O
in	O
Azoospermic	O
Testis	O

ART3	B-GP
protein	O
expression	O
in	O
azoospermic	O
testes	O
was	O
examined	O
by	O
immunohistochemical	O
analysis	O
.	O

As	O
shown	O
in	O
Figure	O
8	O
,	O
specific	O
staining	O
of	O
ART3	B-GP
protein	O
was	O
predominantly	O
observed	O
in	O
spermatocytes	O
in	O
OA	O
testes	O
(	O
Figure	O
8C	O
–	O
8E	O
)	O
as	O
well	O
as	O
in	O
normal	O
testes	O
from	O
individuals	O
of	O
accidental	O
sudden	O
-	O
death	O
(	O
Figure	O
8A	O
and	O
8B	O
).	O

Staining	O
was	O
not	O
observed	O
in	O
other	O
stages	O
of	O
undifferentiated	O
germ	O
cells	O
or	O
Sertoli	O
cells	O
in	O
the	O
seminiferous	O
tubules	O
,	O
or	O
the	O
interstitial	O
tissues	O
such	O
as	O
Leydig	O
cells	O
.	O

On	O
the	O
other	O
hand	O
,	O
we	O
did	O
not	O
detect	O
any	O
ART3	B-GP
protein	O
in	O
NOA	O
testes	O
with	O
Johnsen	O
'	O
s	O
scores	O
ranging	O
from	O
2	O
to	O
3	O
,	O
which	O
showed	O
no	O
spermatocytes	O
,	O
spermatids	O
,	O
or	O
spermatozoa	O
in	O
the	O
seminiferous	O
tubules	O
(	O
n	O
=	O
12	O
samples	O
;	O
Figure	O
8F	O
–	O
8H	O
).	O

There	O
was	O
no	O
marked	O
difference	O
in	O
testicular	O
ART3	B-GP
protein	O
expression	O
among	O
the	O
three	O
ART3	B-GP
diplo	O
-	O
groups	O
carrying	O
none	O
,	O
one	O
,	O
or	O
two	O
copies	O
of	O
haplotype	O
H1	O
.	O

Immunohistochemical	O
Analysis	O
of	O
ART3	B-GP
Expression	O
in	O
Human	B-OG
Testes	O

Representative	O
seminiferous	O
tubules	O
in	O
testicular	O
sections	O
from	O
normal	O
controls	O
(	O
A	O
,	O
B	O
),	O
OA	O
(	O
C	O
–	O
E	O
),	O
and	O
NOA	O
patients	O
(	O
F	O
–	O
H	O
)	O
are	O
shown	O
.	O

Arrows	O
indicate	O
spermatocytes	O
(	O
SPC	O
);	O
spermatids	O
(	O
SPT	O
);	O
and	O
Sertoli	O
cells	O
(	O
SC	O
)	O
(	O
B	O
).	O

ART3	B-GP
protein	O
was	O
immunostained	O
with	O
anti	O
-	O
ART3	B-GP
antibody	O
;	O
ART3	B-GP
-	O
positive	O
spermatocytes	O
(	O
SPC	O
)	O
are	O
noted	O
as	O
brown	O
staining	O
cells	O
(	O
A	O
–	O
E	O
).	O

No	O
marked	O
differences	O
in	O
testicular	O
ART3	B-GP
expression	O
among	O
the	O
three	O
ART3	B-GP
diplo	O
-	O
groups	O
carrying	O
none	O
,	O
one	O
,	O
or	O
two	O
copies	O
of	O
the	O
protective	O
haplotype	O
H1were	O
observed	O
in	O
OA	O
(	O
C	O
–	O
E	O
)	O
and	O
NOA	O
(	O
F	O
–	O
H	O
)	O
patients	O
.	O

Magnification	O
is	O
60	O
×	O
except	O
in	O
(	O
B	O
)	O
(	O
120	O
×).	O

Discussion	O

Genomic	O
Analysis	O
of	O
NOA	O

Our	O
investigation	O
was	O
designed	O
to	O
clarify	O
the	O
pathogenesis	O
of	O
NOA	O
using	O
global	O
gene	O
expression	O
analyses	O
of	O
testis	O
samples	O
from	O
NOA	O
patients	O
and	O
to	O
identify	O
genetic	O
susceptibilities	O
underlying	O
NOA	O
from	O
the	O
genes	O
differentially	O
expressed	O
.	O

Large	O
families	O
with	O
multiple	O
generations	O
having	O
NOA	O
cannot	O
be	O
expected	O
due	O
to	O
the	O
nature	O
of	O
infertility	B-DS
,	O
so	O
linkage	O
study	O
is	O
impractical	O
for	O
NOA	O
and	O
has	O
not	O
been	O
reported	O
.	O

Alternatively	O
,	O
allelic	O
association	O
study	O
is	O
a	O
practical	O
approach	O
to	O
identification	O
of	O
genetic	O
susceptibility	O
underlying	O
NOA	O
.	O

Thus	O
far	O
,	O
more	O
than	O
80	O
genes	O
have	O
been	O
identified	O
as	O
essential	O
for	O
male	B-DS
infertility	I-DS
in	O
humans	B-OG
and	O
mice	B-OG
[	O
3	O
].	O

Genes	O
on	O
the	O
Y	O
chromosome	O
were	O
emphasized	O
because	O
of	O
observed	O
microdeletions	O
in	O
patients	O
,	O
and	O
genes	O
such	O
as	O
DAZ	B-GP
and	O
HSFY	B-GP
were	O
examined	O
for	O
possible	O
susceptibility	O
genes	O
[	O
28	O
,	O
29	O
].	O

Recently	O
,	O
homozygous	O
mutation	O
of	O
the	O
aurora	B-GP
kinase	I-GP
C	I-GP
gene	O
was	O
identified	O
in	O
large	O
-	O
headed	O
multiflagellar	O
polyploid	O
spermatozoa	O
,	O
a	O
rare	O
form	O
of	O
infertility	B-DS
,	O
using	O
homozygosity	O
mapping	O
[	O
30	O
].	O

In	O
the	O
current	O
study	O
,	O
we	O
applied	O
a	O
novel	O
approach	O
to	O
identify	O
common	O
susceptibility	O
genes	O
for	O
NOA	O
by	O
applying	O
global	O
gene	O
expression	O
analysis	O
of	O
NOA	O
testes	O
.	O

Based	O
on	O
the	O
hypothesis	O
that	O
a	O
common	O
variant	O
of	O
a	O
susceptibility	O
gene	O
has	O
resulted	O
in	O
altered	O
expression	O
in	O
tissues	O
relevant	O
to	O
disease	O
etiology	O
[	O
31	O
],	O
we	O
first	O
elucidated	O
the	O
gene	O
expression	O
profile	O
in	O
testes	O
of	O
NOA	O
patients	O
and	O
characterized	O
the	O
genetic	O
pathways	O
that	O
were	O
either	O
under	O
-	O
expressed	O
or	O
over	O
-	O
expressed	O
.	O

Because	O
spermatogenesis	O
is	O
a	O
complex	O
differentiation	O
process	O
,	O
NOA	O
could	O
result	O
from	O
a	O
defect	O
at	O
any	O
stage	O
of	O
the	O
process	O
.	O

Thus	O
,	O
gene	O
expression	O
profiling	O
of	O
NOA	O
tissues	O
might	O
well	O
be	O
confounded	O
by	O
the	O
difficulty	O
of	O
discerning	O
the	O
differential	O
stage	O
and	O
the	O
pathological	O
status	O
.	O

Feig	O
et	O
al	O
.	O
[	O
4	O
]	O
examined	O
stage	O
-	O
specific	O
gene	O
expression	O
profiles	O
in	O
human	B-OG
NOA	O
patients	O
after	O
classification	O
on	O
the	O
basis	O
of	O
Johnsen	O
'	O
s	O
score	O
.	O

The	O
testis	O
tissues	O
were	O
classified	O
into	O
four	O
groups	O
showing	O
Sertoli	B-DS
-	I-DS
cell	I-DS
only	I-DS
syndrome	I-DS
,	O
meiotic	O
arrest	O
,	O
testicular	O
hypospermia	O
,	O
and	O
testicular	O
normospermia	O
,	O
corresponding	O
to	O
Johnsen	O
'	O
s	O
score	O
2	O
,	O
5	O
,	O
8	O
,	O
and	O
10	O
,	O
respectively	O
,	O
and	O
stage	O
-	O
specific	O
differential	O
gene	O
expression	O
was	O
monitored	O
.	O

We	O
sought	O
to	O
identify	O
susceptibility	O
genes	O
underlying	O
NOA	O
that	O
could	O
affect	O
any	O
stage	O
of	O
spermatogenesis	O
.	O

Testis	O
samples	O
subgrouped	O
according	O
to	O
Johnsen	O
'	O
s	O
score	O
in	O
advance	O
might	O
identify	O
genes	O
affecting	O
multiple	O
stages	O
of	O
spermatogenesis	O
.	O

Therefore	O
,	O
we	O
globally	O
subgrouped	O
the	O
samples	O
at	O
diverse	O
stages	O
of	O
differentiation	O
using	O
an	O
NMF	O
method	O
for	O
reducing	O
multidimensionality	O
that	O
is	O
appropriate	O
for	O
application	O
to	O
high	O
dimensional	O
biological	O
data	O
.	O

The	O
NMF	O
method	O
subgrouped	O
three	O
classes	O
,	O
NOA1	O
,	O
NOA2	O
,	O
and	O
NOA3	O
,	O
which	O
also	O
were	O
unequivocally	O
subgrouped	O
by	O
the	O
HC	O
approach	O
(	O
Figure	O
3	O
).	O

Notably	O
,	O
NOA1	O
and	O
NOA2	O
represent	O
a	O
pathologically	O
similar	O
type	O
showing	O
low	O
Johnsen	O
'	O
s	O
score	O
,	O
but	O
were	O
subclassified	O
because	O
of	O
their	O
distinct	O
gene	O
expression	O
pattern	O
.	O

NOA1	O
and	O
NOA2	O
showed	O
differences	O
in	O
LH	B-GP
,	O
FSH	B-GP
,	O
and	O
testosterone	O
levels	O
,	O
thus	O
establishing	O
meaningful	O
biological	O
significance	O
of	O
the	O
sub	O
-	O
classes	O
(	O
Table	O
2	O
).	O

Genetic	O
Susceptibility	O
to	O
NOA	O

In	O
the	O
current	O
study	O
,	O
we	O
adopted	O
a	O
novel	O
approach	O
to	O
select	O
candidate	O
susceptibility	O
genes	O
for	O
NOA	O
.	O

Global	O
gene	O
expression	O
analyses	O
were	O
performed	O
on	O
NOA	O
testes	O
,	O
and	O
52	O
genes	O
were	O
selected	O
according	O
to	O
differential	O
gene	O
expression	O
between	O
NOA	O
subclasses	O
with	O
a	O
strict	O
statistical	O
criterion	O
(	O
p	O
<	O
0	O
.	O
01	O
with	O
Tukey	O
'	O
s	O
post	O
hoc	O
test	O
).	O

Despite	O
the	O
fact	O
that	O
our	O
selection	O
criteria	O
relied	O
only	O
on	O
data	O
regarding	O
differences	O
in	O
gene	O
expression	O
and	O
did	O
not	O
include	O
any	O
biological	O
assumptions	O
,	O
many	O
of	O
the	O
genes	O
were	O
related	O
to	O
spermatogenesis	O
based	O
on	O
Gene	O
Ontology	O
analyses	O
(	O
Figure	O
4	O
;	O
Table	O
1	O
).	O

191	O
SNPs	O
of	O
42	O
genes	O
were	O
screened	O
,	O
and	O
only	O
one	O
gene	O
,	O
ART3	B-GP
,	O
showed	O
a	O
positive	O
association	O
after	O
the	O
two	O
rounds	O
of	O
screening	O
.	O

Multiple	O
SNPs	O
of	O
ART3	B-GP
were	O
significantly	O
associated	O
with	O
NOA	O
,	O
the	O
most	O
significant	O
association	O
being	O
observed	O
with	O
ART3	B-GP
-	O
SNP25	O
(	O
rs6836703	O
,	O
nominal	O
p	O
=	O
0	O
.	O
0025	O
,	O
permutation	O
p	O
=	O
0	O
.	O
034	O
;	O
Table	O
4	O
).	O

We	O
also	O
detected	O
a	O
protective	O
haplotype	O
,	O
H1	O
,	O
which	O
was	O
the	O
most	O
common	O
form	O
and	O
was	O
strongly	O
associated	O
with	O
NOA	O
(	O
nominal	O
p	O
=	O
0	O
.	O
000073	O
,	O
corrected	O
p	O
=	O
0	O
.	O
00080	O
,	O
Figure	O
6	O
).	O

In	O
addition	O
,	O
diplotype	O
analysis	O
showed	O
that	O
individuals	O
carrying	O
at	O
least	O
one	O
haplotype	O
H1	O
showed	O
an	O
elevated	O
plasma	O
testosterone	O
level	O
(	O
Figure	O
7	O
).	O

Functional	O
Relevance	O
of	O
ART3	B-GP
in	O
the	O
Pathogenesis	O
of	O
NOA	O

ART3	B-GP
is	O
a	O
member	O
of	O
the	O
mono	O
-	O
ADP	B-GP
-	I-GP
ribosyltransferase	I-GP
family	O
genes	O
.	O

The	O
biological	O
function	O
of	O
ART3	B-GP
remains	O
obscure	O
,	O
as	O
ART3	B-GP
does	O
not	O
display	O
any	O
detectable	O
arginine	O
-	O
specific	O
transferase	B-GP
activity	O
due	O
to	O
lack	O
of	O
the	O
active	O
site	O
motif	O
(	O
R	O
-	O
S	O
-	O
EXE	O
)	O
that	O
is	O
essential	O
for	O
catalytic	O
activity	O
.	O

Since	O
differentiation	O
of	O
stage	O
-	O
specific	O
expression	O
of	O
ART3	B-GP
in	O
testis	O
has	O
been	O
reported	O
,	O
protein	O
expression	O
being	O
exclusively	O
present	O
in	O
spermatocytes	O
but	O
absent	O
in	O
spermatozoa	O
[	O
32	O
],	O
a	O
genetic	O
variation	O
of	O
ART3	B-GP
might	O
well	O
lead	O
to	O
a	O
functional	O
defect	O
in	O
the	O
process	O
of	O
spermatogenesis	O
.	O

Haplotype	O
H1	O
of	O
ART3	B-GP
,	O
comprising	O
all	O
of	O
the	O
disease	O
-	O
protective	O
alleles	O
at	O
the	O
respective	O
SNP	O
sites	O
,	O
was	O
under	O
-	O
represented	O
in	O
the	O
patients	O
.	O

However	O
,	O
functional	O
disturbance	O
associated	O
with	O
haplotype	O
H1	O
is	O
so	O
far	O
undetermined	O
despite	O
the	O
fact	O
that	O
several	O
experiments	O
designed	O
to	O
demonstrate	O
haplotype	O
-	O
specific	O
differences	O
in	O
expression	O
level	O
have	O
been	O
performed	O
.	O

Thus	O
,	O
it	O
is	O
possible	O
that	O
this	O
haplotype	O
represents	O
fine	O
tuning	O
that	O
maintains	O
normal	O
maturation	O
of	O
spermatocytes	O
and	O
improves	O
the	O
efficiency	O
of	O
spermatogenesis	O
.	O

In	O
conclusion	O
,	O
genome	O
-	O
wide	O
gene	O
expression	O
analyses	O
identified	O
differentially	O
expressed	O
genes	O
of	O
NOA	O
subclasses	O
,	O
and	O
ART3	B-GP
was	O
identified	O
as	O
a	O
susceptibility	O
gene	O
underlying	O
NOA	O
.	O

This	O
genetic	O
study	O
constitutes	O
only	O
first	O
-	O
stage	O
evidence	O
of	O
association	O
because	O
only	O
Japanese	O
individuals	O
were	O
included	O
,	O
so	O
further	O
replication	O
in	O
independent	O
case	O
-	O
control	O
samples	O
is	O
required	O
to	O
confirm	O
the	O
role	O
of	O
the	O
ART3	B-GP
haplotype	O
in	O
genetic	O
risk	O
for	O
NOA	O
.	O

Although	O
further	O
functional	O
evidence	O
is	O
also	O
required	O
,	O
these	O
results	O
provide	O
insight	O
into	O
the	O
pathoetiology	O
of	O
NOA	O
as	O
well	O
as	O
reproductive	O
fitness	O
at	O
the	O
molecular	O
level	O
,	O
and	O
suggest	O
a	O
target	O
for	O
therapy	O
.	O

Materials	O
and	O
Methods	O

Participants	O
.	O

Testicular	O
biopsy	O
specimens	O
for	O
microarray	O
analysis	O
were	O
obtained	O
from	O
47	O
Japanese	O
patients	O
(	O
aged	O
from	O
24	O
to	O
52	O
years	O
)	O
with	O
NOA	O
and	O
11	O
(	O
aged	O
from	O
22	O
to	O
57	O
years	O
)	O
with	O
OA	O
,	O
each	O
of	O
whom	O
also	O
underwent	O
testicular	O
sperm	O
extraction	O
(	O
TESE	O
)	O
for	O
assisted	O
reproduction	O
and	O
/	O
or	O
diagnostic	O
biopsy	O
for	O
histological	O
examination	O
.	O

The	O
biopsies	O
for	O
microarray	O
analysis	O
and	O
histological	O
examination	O
were	O
mainly	O
sampled	O
from	O
unilateral	O
,	O
multiple	O
testicular	O
sites	O
in	O
the	O
respective	O
patients	O
.	O

Each	O
patient	O
was	O
first	O
assigned	O
to	O
azoospermia	B-DS
by	O
showing	O
no	O
ejaculated	O
spermatozoa	O
in	O
a	O
semen	O
examination	O
.	O

Subsequently	O
,	O
OA	O
was	O
defined	O
as	O
follows	O
:	O
(	O
1	O
)	O
motile	O
spermatozoa	O
were	O
sampled	O
from	O
microsurgical	O
epididymal	O
sperm	O
aspiration	O
(	O
MESA	O
),	O
or	O
(	O
2	O
)	O
a	O
considerable	O
number	O
of	O
mature	O
spermatozoa	O
was	O
sampled	O
from	O
TESE	O
.	O

NOA	O
was	O
tentatively	O
defined	O
as	O
having	O
no	O
epididymal	O
and	O
/	O
or	O
testicular	O
spermatozoa	O
.	O

The	O
degree	O
of	O
spermatogenic	O
defect	O
was	O
histologically	O
evaluated	O
according	O
to	O
Johnsen	O
'	O
s	O
score	O
[	O
11	O
].	O

At	O
least	O
three	O
biopsies	O
from	O
the	O
same	O
individual	O
were	O
taken	O
,	O
and	O
the	O
average	O
Johnsen	O
'	O
s	O
scores	O
in	O
the	O
NOA	O
and	O
OA	O
groups	O
ranged	O
from	O
1	O
to	O
6	O
.	O
5	O
and	O
from	O
5	O
.	O
1	O
to	O
9	O
,	O
respectively	O
.	O

In	O
most	O
patients	O
,	O
preoperative	O
levels	O
of	O
serum	O
follicle	B-GP
-	I-GP
stimulating	I-GP
hormone	I-GP
(	O
FSH	B-GP
),	O
leutenizing	B-GP
hormone	I-GP
(	O
LH	B-GP
),	O
and	O
total	O
testosterone	O
were	O
measured	O
.	O

The	O
infertile	B-DS
male	O
patients	O
who	O
visited	O
Niigata	O
University	O
,	O
Tachikawa	O
Hospital	O
,	O
and	O
St	O
.	O
Mother	O
'	O
s	O
Hospital	O
received	O
a	O
routine	O
semen	O
examination	O
according	O
to	O
1999	O
WHO	O
criteria	O
.	O

Based	O
on	O
this	O
analysis	O
,	O
sperm	O
were	O
counted	O
and	O
the	O
patients	O
who	O
had	O
no	O
ejaculated	O
sperms	O
were	O
enrolled	O
for	O
a	O
case	O
-	O
control	O
association	O
study	O
.	O

In	O
total	O
,	O
442	O
patients	O
were	O
ascertained	O
to	O
have	O
NOA	O
.	O

In	O
the	O
current	O
study	O
,	O
azoospermia	B-DS
patients	O
with	O
varicocele	B-DS
,	O
ejaculatory	O
dysfunction	O
,	O
endocrinopathy	B-DS
,	O
or	O
histologically	O
examined	O
OA	O
as	O
defined	O
above	O
were	O
excluded	O
.	O

475	O
fertile	O
men	O
having	O
no	O
specific	O
clinical	O
record	O
were	O
recruited	O
in	O
Niigata	O
University	O
.	O

The	O
ethics	O
committees	O
of	O
Niigata	O
University	O
,	O
Tachikawa	O
Hospital	O
,	O
St	O
.	O
Mother	O
'	O
s	O
Hospital	O
,	O
and	O
Tokai	O
University	O
approved	O
the	O
study	O
protocols	O
,	O
and	O
each	O
participant	O
gave	O
written	O
informed	O
consent	O
.	O

Genomic	O
DNA	O
was	O
prepared	O
from	O
blood	O
white	O
cells	O
by	O
Dneasy	O
(	O
Qiagen	O
,	O
Tokyo	O
,	O
Japan	O
)	O
or	O
salivas	O
by	O
phenol	O
/	O
chloroform	O
extraction	O
.	O

To	O
examine	O
microdeletion	O
of	O
the	O
Y	O
chromosome	O
in	O
a	O
subset	O
of	O
NOA	O
patients	O
,	O
PCR	O
-	O
based	O
diagnostic	O
technique	O
was	O
used	O
as	O
follows	O
:	O
PCR	O
amplifications	O
with	O
fluorescence	O
(	O
FAM	O
or	O
HEX	O
)-	O
labeled	O
primers	O
were	O
performed	O
to	O
obtain	O
fragments	O
encompassing	O
each	O
of	O
13	O
STS	O
markers	O
in	O
and	O
around	O
azoospermia	B-GP
factor	I-GP
(	O
AZF	B-GP
)	O
regions	O
of	O
the	O
Y	O
chromosome	O
(	O
in	O
AZFa	O
:	O
SY83	O
,	O
SY95	O
and	O
SY105	O
;	O
in	O
AZFb	O
:	O
SY118	O
,	O
G65320	O
,	O
SY126	O
and	O
SY136	O
;	O
in	O
AZFc	O
:	O
SY148	O
,	O
SY149	O
,	O
SY152	O
,	O
SY283	O
and	O
SY1291	O
;	O
in	O
the	O
heterochromatin	O
distal	O
to	O
AZFc	O
:	O
SY166	O
).	O

Primer	O
sequences	O
and	O
PCR	O
conditions	O
are	O
available	O
from	O
the	O
authors	O
on	O
request	O
.	O

PCR	O
-	O
amplified	O
fragments	O
were	O
run	O
on	O
the	O
ABI	O
PRISM	O
3100	O
Genetic	O
Analyzer	O
(	O
Applied	O
Biosystems	O
,	O
Tokyo	O
,	O
Japan	O
),	O
and	O
Y	O
-	O
chromosome	O
microdeletion	O
was	O
determined	O
with	O
GENESCAN	O
software	O
(	O
Applied	O
Biosystems	O
).	O

Microarray	O
analysis	O
of	O
testis	O
samples	O
.	O

Total	O
RNA	O
from	O
testicular	O
biopsy	O
was	O
extracted	O
using	O
TRIzol	O
reagent	O
(	O
Invitrogen	O
,	O
Carlsbad	O
,	O
CA	O
,	O
USA	O
)	O
and	O
quantity	O
and	O
quality	O
of	O
the	O
extracted	O
RNA	O
were	O
examined	O
with	O
2100	O
Bioanalyzer	O
(	O
Agilent	O
Technologies	O
,	O
Palo	O
Alto	O
,	O
CA	O
,	O
USA	O
)	O
using	O
RNA	O
6000	O
Nano	O
LabChip	O
(	O
Agilent	O
Technologies	O
).	O

Human	B-OG
Testis	O
Total	O
RNA	O
(	O
BD	O
Biosciences	O
,	O
San	O
Jose	O
,	O
CA	O
,	O
USA	O
),	O
a	O
histologically	O
normal	O
testicular	O
RNA	O
pooled	O
from	O
39	O
Caucasians	O
,	O
was	O
used	O
as	O
a	O
common	O
reference	O
in	O
two	O
-	O
color	O
microarray	O
experiments	O
.	O

For	O
fluorescent	O
cRNA	O
synthesis	O
,	O
high	O
-	O
quality	O
total	O
RNA	O
(	O
150	O
ng	O
)	O
was	O
labeled	O
with	O
the	O
Low	O
RNA	O
Input	O
Fluorescent	O
Linear	O
Amplification	O
Kit	O
(	O
Agilent	O
Technologies	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

In	O
this	O
procedure	O
,	O
cyanine	O
5	O
-	O
CTP	O
(	O
Cy5	O
)	O
and	O
cyanine	O
3	O
-	O
CTP	O
(	O
Cy3	O
)	O
(	O
PerkinElmer	O
,	O
Boston	O
,	O
MA	O
,	O
USA	O
)	O
were	O
used	O
to	O
generate	O
labeled	O
cRNA	O
from	O
the	O
extracted	O
patient	O
RNA	O
and	O
the	O
reference	O
RNA	O
,	O
respectively	O
.	O

Labeled	O
cRNAs	O
(	O
0	O
.	O
75	O
μg	O
each	O
)	O
from	O
one	O
patient	O
and	O
the	O
common	O
reference	O
were	O
combined	O
and	O
fragmented	O
in	O
a	O
hybridization	O
mixture	O
with	O
the	O
In	O
Situ	O
Hybridization	O
Kit	O
Plus	O
(	O
Agilent	O
Technologies	O
).	O

The	O
mixture	O
was	O
hybridized	O
for	O
17	O
hours	O
at	O
65	O
°	O
C	O
to	O
the	O
Agilent	O
Human	B-OG
1A	O
(	O
v2	O
)	O
Oligo	O
Microarray	O
,	O
which	O
carries	O
60	O
-	O
mer	O
probes	O
to	O
18	O
,	O
716	O
human	B-OG
transcripts	O
.	O

After	O
hybridization	O
,	O
the	O
microarray	O
was	O
washed	O
with	O
SSC	O
buffer	O
,	O
and	O
then	O
scanned	O
in	O
Cy3	O
and	O
Cy5	O
channels	O
with	O
the	O
Agilent	O
DNA	O
Microarray	O
Scanner	O
model	O
G2565AA	O
(	O
Agilent	O
Technologies	O
).	O

Signal	O
intensity	O
per	O
spot	O
was	O
generated	O
from	O
the	O
scanned	O
image	O
with	O
Feature	O
Extraction	O
Software	O
ver7	O
.	O
5	O
(	O
Agilent	O
Technologies	O
)	O
in	O
default	O
setting	O
.	O

Spots	O
that	O
did	O
not	O
pass	O
quality	O
control	O
procedures	O
were	O
flagged	O
and	O
removed	O
for	O
further	O
analysis	O
.	O

The	O
Lowess	O
(	O
locally	O
weighted	O
linear	O
regression	O
curve	O
fit	O
)	O
method	O
was	O
applied	O
to	O
normalize	O
the	O
ratio	O
(	O
Cy5	O
/	O
Cy3	O
)	O
of	O
the	O
signal	O
intensities	O
generated	O
in	O
each	O
microarray	O
with	O
GeneSpring	O
GX	O
7	O
.	O
3	O
(	O
Agilent	O
Technologies	O
).	O

Compared	O
with	O
the	O
expression	O
level	O
of	O
reference	O
RNA	O
,	O
the	O
NOA	O
group	O
,	O
with	O
expression	O
undergoing	O
a	O
2	O
-	O
fold	O
mean	O
change	O
or	O
more	O
was	O
extracted	O
;	O
the	O
OA	O
group	O
comprised	O
transcripts	O
showing	O
less	O
than	O
2	O
-	O
fold	O
mean	O
expression	O
change	O
(	O
Figure	O
1A	O
).	O

Of	O
the	O
transcripts	O
included	O
in	O
both	O
groups	O
,	O
only	O
those	O
with	O
a	O
statistically	O
significant	O
difference	O
in	O
expression	O
between	O
NOA	O
and	O
OA	O
testes	O
(	O
based	O
on	O
lowess	O
-	O
normalized	O
natural	O
log	O
[	O
Cy5	O
/	O
Cy3	O
],	O
Bonferroni	O
'	O
s	O
corrected	O
p	O
<	O
0	O
.	O
05	O
)	O
were	O
counted	O
as	O
NOA	O
-	O
related	O
target	O
genes	O
.	O

To	O
elucidate	O
the	O
molecular	O
subtypes	O
of	O
NOA	O
,	O
we	O
adopted	O
the	O
non	O
-	O
negative	O
matrix	O
factorization	O
(	O
NMF	O
)	O
algorithm	O
,	O
which	O
has	O
been	O
recently	O
introduced	O
to	O
analysis	O
of	O
gene	O
expression	O
data	O
[	O
5	O
,	O
6	O
].	O

For	O
this	O
analysis	O
,	O
a	O
complete	O
dataset	O
without	O
missing	O
values	O
was	O
generated	O
from	O
raw	O
values	O
of	O
Cy5	O
intensities	O
for	O
the	O
NOA	O
-	O
related	O
target	O
genes	O
in	O
the	O
NOA	O
samples	O
,	O
and	O
used	O
to	O
clarify	O
NOA	O
heterogeneity	O
using	O
three	O
M	O
-	O
files	O
(	O
available	O
from	O
the	O
following	O
URL	O
;	O
http	O
://	O
www	O
.	O
broad	O
.	O
mit	O
.	O
edu	O
/	O
cgi	O
-	O
bin	O
/	O
cancer	O
/	O
publications	O
/	O
pub_paper	O
.	O
cgi	O
?	O
mode	O
=	O
view	O
&	O
paper_id	O
=	O
89	O
)	O
for	O
MATLAB	O
(	O
Mathworks	O
,	O
Natick	O
,	O
MA	O
,	O
USA	O
).	O

According	O
to	O
the	O
subclassification	O
of	O
NOA	O
samples	O
,	O
transcripts	O
differentially	O
expressed	O
between	O
NOA	O
subclasses	O
were	O
determined	O
by	O
one	O
-	O
way	O
ANOVA	O
,	O
followed	O
by	O
Tukey	O
'	O
s	O
post	O
hoc	O
test	O
in	O
GeneSpring	O
GX	O
.	O

For	O
multiple	O
test	O
corrections	O
in	O
this	O
statistical	O
analysis	O
,	O
we	O
used	O
the	O
Benjamini	O
-	O
Hochberg	O
procedure	O
[	O
33	O
]	O
of	O
controlling	O
the	O
false	O
discovery	O
rate	O
(	O
FDR	O
)	O
at	O
the	O
level	O
of	O
0	O
.	O
05	O
or	O
0	O
.	O
01	O
.	O

To	O
analyze	O
which	O
categories	O
of	O
Gene	O
Ontology	O
were	O
statistically	O
overrepresented	O
among	O
the	O
gene	O
lists	O
obtained	O
,	O
we	O
used	O
GO	O
Browser	O
,	O
an	O
optional	O
tool	O
in	O
GeneSpring	O
GX	O
,	O
where	O
the	O
statistical	O
significance	O
was	O
determined	O
by	O
Fisher	O
'	O
s	O
exact	O
test	O
.	O

The	O
microarray	O
data	O
reported	O
in	O
this	O
paper	O
have	O
been	O
deposited	O
in	O
the	O
Gene	O
Expression	O
Omnibus	O
(	O
GEO	O
,	O
http	O
://	O
www	O
.	O
ncbi	O
.	O
nlm	O
.	O
nih	O
.	O
gov	O
/	O
geo	O
/)	O
database	O
,	O
and	O
are	O
accessible	O
through	O
GEO	O
Series	O
accession	O
number	O
GSE9210	O
.	O

Quantitative	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
analysis	O
for	O
validation	O
of	O
between	O
-	O
subclass	O
differences	O
in	O
gene	O
expression	O
.	O

Quantitative	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
analysis	O
was	O
used	O
to	O
verify	O
the	O
microarray	O
data	O
on	O
53	O
transcripts	O
representing	O
differential	O
expressions	O
between	O
NOA	O
subclasses	O
with	O
high	O
significance	O
(	O
p	O
<	O
0	O
.	O
01	O
).	O

Among	O
53	O
transcripts	O
,	O
VCX	B-GP
(	O
NM_013452	O
),	O
VCX2	B-GP
(	O
NM_016378	O
),	O
and	O
VCX3A	B-GP
(	O
NM_016379	O
)	O
were	O
examined	O
as	O
a	O
single	O
transcript	O
because	O
sequence	O
homologies	O
between	O
the	O
three	O
transcripts	O
prevented	O
development	O
of	O
appropriate	O
assays	O
for	O
discrimination	O
.	O

Testicular	O
total	O
RNA	O
(	O
1	O
μg	O
)	O
subjected	O
to	O
microarray	O
analysis	O
was	O
used	O
as	O
a	O
template	O
in	O
first	O
-	O
strand	O
cDNA	O
synthesis	O
with	O
SuperScript	O
III	O
First	O
-	O
Strand	O
Synthesis	O
System	O
(	O
Invitrogen	O
).	O

Each	O
single	O
-	O
stranded	O
cDNA	O
was	O
diluted	O
one	O
-	O
tenth	O
for	O
a	O
subsequent	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
using	O
SYBR	O
Premix	O
Ex	O
Taq	O
(	O
Perfect	O
Real	O
Time	O
)	O
(	O
TAKARA	O
BIO	O
,	O
Otsu	O
,	O
Japan	O
)	O
on	O
the	O
ABI	O
PRISM	O
7900HT	O
Sequence	O
Detection	O
System	O
(	O
Applied	O
Biosystems	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

The	O
PCR	O
primers	O
for	O
43	O
transcripts	O
showing	O
between	O
-	O
subclass	O
differences	O
with	O
high	O
significance	O
and	O
GAPDH	B-GP
were	O
designed	O
and	O
synthesized	O
by	O
TAKARA	O
BIO	O
Inc	O
.,	O
or	O
QIAGEN	O
GmbH	O
(	O
as	O
the	O
QuantiTect	O
Primer	O
Assay	O
).	O

In	O
the	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
analysis	O
for	O
the	O
nine	O
remaining	O
transcripts	O
,	O
we	O
used	O
TaqMan	O
Gene	O
Expression	O
Assays	O
(	O
Applied	O
Biosystems	O
)	O
with	O
TaqMan	O
Universal	O
PCR	O
Master	O
Mix	O
(	O
No	O
AmpErase	O
UNG	O
version	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
(	O
Applied	O
Biosystems	O
).	O

The	O
detailed	O
information	O
on	O
the	O
primer	O
sequences	O
used	O
and	O
/	O
or	O
the	O
assay	O
system	O
selected	O
are	O
summarized	O
in	O
Table	O
S3	O
.	O

A	O
relative	O
quantification	O
method	O
[	O
34	O
]	O
was	O
used	O
to	O
measure	O
the	O
amounts	O
of	O
the	O
respective	O
genes	O
in	O
NOA	O
testes	O
,	O
normalized	O
to	O
GAPDH	B-GP
as	O
an	O
endogenous	O
control	O
,	O
and	O
relative	O
to	O
Human	B-OG
Testis	O
Total	O
RNA	O
(	O
BD	O
Biosciences	O
)	O
as	O
a	O
reference	O
RNA	O
.	O

Statistical	O
significance	O
between	O
NOA	O
subclasses	O
was	O
determined	O
by	O
Kruskal	O
-	O
Wallis	O
test	O
,	O
followed	O
by	O
multiple	O
comparisons	O
;	O
p	O
<	O
0	O
.	O
05	O
was	O
considered	O
significant	O
.	O

SNP	O
selection	O
of	O
candidate	O
genes	O
for	O
NOA	O
and	O
genotyping	O
.	O

Based	O
on	O
gene	O
expression	O
data	O
of	O
NOA	O
testes	O
,	O
we	O
selected	O
52	O
genes	O
(	O
encoding	O
53	O
transcripts	O
)	O
as	O
candidates	O
for	O
genetic	O
susceptibilities	O
underlying	O
NOA	O
.	O

SNPs	O
of	O
the	O
candidate	O
genes	O
with	O
minor	O
allele	O
frequency	O
(	O
MAF	O
)	O
>	O
0	O
.	O
05	O
were	O
obtained	O
from	O
the	O
NCBI	O
dbSNP	O
database	O
(	O
http	O
://	O
www	O
.	O
ncbi	O
.	O
nlm	O
.	O
nih	O
.	O
gov	O
/	O
SNP	O
/),	O
and	O
applied	O
to	O
an	O
initial	O
screening	O
.	O

Of	O
the	O
52	O
candidate	O
genes	O
,	O
10	O
genes	O
(	O
CTAG1B	B-GP
,	O
LOC158812	O
,	O
LOC255313	O
,	O
MAGEA2	B-GP
,	O
PEPP	B-GP
-	I-GP
2	I-GP
,	O
TSPY1	B-GP
,	O
TSPY2	B-GP
,	O
VCX3A	B-GP
,	O
VCY	B-GP
,	O
and	O
XAGE1	B-GP
)	O
were	O
excluded	O
from	O
the	O
initial	O
screening	O
because	O
gene	O
-	O
based	O
SNPs	O
with	O
MAF	O
>	O
0	O
.	O
05	O
were	O
not	O
found	O
in	O
the	O
public	O
SNP	O
database	O
.	O

A	O
total	O
of	O
191	O
SNPs	O
of	O
42	O
genes	O
were	O
genotyped	O
in	O
the	O
screening	O
with	O
TaqMan	O
SNP	O
Genotyping	O
Assays	O
on	O
the	O
ABI	O
PRISM	O
7900HT	O
Sequence	O
Detection	O
System	O
(	O
Applied	O
Biosystems	O
).	O

190	O
NOA	O
patients	O
(	O
cases	O
)	O
and	O
190	O
fertile	O
men	O
(	O
controls	O
)	O
were	O
genotyped	O
in	O
the	O
first	O
round	O
screening	O
.	O

For	O
genes	O
with	O
at	O
least	O
one	O
SNP	O
showing	O
a	O
discrepancy	O
in	O
MAF	O
of	O
5	O
%	O
or	O
greater	O
between	O
cases	O
and	O
controls	O
,	O
the	O
sample	O
size	O
was	O
increased	O
to	O
380	O
cases	O
and	O
380	O
controls	O
in	O
the	O
second	O
round	O
.	O

After	O
two	O
rounds	O
of	O
initial	O
screening	O
,	O
additional	O
SNPs	O
of	O
ART3	B-GP
were	O
selected	O
from	O
dbSNP	O
or	O
identified	O
by	O
direct	O
sequencing	O
of	O
all	O
12	O
exons	O
of	O
the	O
gene	O
(	O
Ensemble	O
transcript	O
ID	O
ENST00000355810	O
)	O
and	O
splice	O
acceptor	O
and	O
donor	O
sites	O
in	O
the	O
intron	O
using	O
the	O
genomic	O
DNAs	O
from	O
95	O
infertile	B-DS
patients	O
as	O
PCR	O
templates	O
.	O

A	O
total	O
of	O
38	O
SNPs	O
of	O
ART3	B-GP
were	O
finally	O
genotyped	O
on	O
442	O
cases	O
and	O
475	O
controls	O
by	O
TaqMan	O
SNP	O
Genotyping	O
Assays	O
or	O
by	O
direct	O
sequencing	O
with	O
BigDye	O
Terminators	O
v3	O
.	O
1	O
Cycle	O
Sequencing	O
Kit	O
(	O
Applied	O
Biosystems	O
)	O
on	O
ABI	O
PRISM	O
3700	O
DNA	O
analyzer	O
.	O

Statistical	O
analyses	O
in	O
association	O
study	O
.	O

Pairwise	O
linkage	O
disequilibrium	O
(	O
LD	O
),	O
using	O
the	O
standard	O
definition	O
of	O
D	O
'	O
and	O
r	O
2	O
[	O
35	O
,	O
36	O
],	O
was	O
measured	O
with	O
SNPAlyze	O
v5	O
.	O
0	O
software	O
(	O
DYNACOM	O
,	O
Mobara	O
,	O
Japan	O
).	O

To	O
construct	O
ART3	B-GP
haplotypes	O
in	O
phase	O
-	O
unknown	O
samples	O
,	O
tag	O
SNPs	O
of	O
ART3	B-GP
were	O
selected	O
with	O
Tagger	O
software	O
[	O
25	O
],	O
incorporated	O
in	O
the	O
Haploview	O
.	O

The	O
expectation	O
-	O
maximization	O
(	O
EM	O
)	O
algorithm	O
[	O
37	O
]	O
and	O
PHASE	O
version	O
2	O
.	O
1	O
.	O
1	O
[	O
26	O
,	O
27	O
]	O
was	O
used	O
to	O
infer	O
haplotype	O
frequencies	O
and	O
individual	O
diplotypes	O
for	O
ART3	B-GP
.	O

Differences	O
in	O
allelic	O
and	O
haplotype	O
frequencies	O
were	O
evaluated	O
using	O
a	O
case	O
-	O
control	O
design	O
with	O
the	O
chi	O
-	O
square	O
test	O
.	O

For	O
an	O
adjustment	O
of	O
multiple	O
testing	O
,	O
we	O
applied	O
a	O
permutation	O
method	O
with	O
Haploview	O
version	O
3	O
.	O
32	O
software	O
,	O
or	O
Bonferroni	O
'	O
s	O
method	O
to	O
determine	O
corrected	O
p	O
-	O
values	O
.	O

To	O
investigate	O
association	O
of	O
the	O
ART3	B-GP
diplotype	O
with	O
clinical	O
phenotypes	O
such	O
as	O
serum	O
hormone	O
levels	O
,	O
differences	O
among	O
the	O
three	O
categories	O
(	O
code	O
0	O
,	O
1	O
,	O
and	O
2	O
),	O
defined	O
by	O
the	O
number	O
of	O
the	O
most	O
significant	O
haplotype	O
,	O
were	O
statistically	O
examined	O
by	O
Kruskal	O
-	O
Wallis	O
test	O
,	O
followed	O
by	O
Bonferroni	O
/	O
Dunn	O
post	O
hoc	O
test	O
(	O
StatView	O
version	O
5	O
.	O
0	O
,	O
SAS	O
Institute	O
,	O
Cary	O
,	O
NC	O
,	O
USA	O
).	O

Immunohistochemistry	O
.	O

To	O
examine	O
cellular	O
localization	O
of	O
ART3	B-GP
protein	O
in	O
azoospermic	O
testes	O
,	O
testicular	O
biopsy	O
specimens	O
from	O
15	O
OA	O
and	O
12	O
NOA	O
patients	O
were	O
subjected	O
to	O
immunohistochemistry	O
.	O

Four	O
postmortem	O
testicular	O
tissues	O
of	O
accidental	O
sudden	O
-	O
deaths	O
were	O
used	O
as	O
normal	O
controls	O
.	O

The	O
testicular	O
tissues	O
were	O
fixed	O
in	O
10	O
%	O
buffered	O
formalin	O
and	O
embedded	O
in	O
paraffin	O
.	O

Cryosections	O
(	O
3	O
μm	O
thickness	O
)	O
were	O
pre	O
-	O
incubated	O
with	O
the	O
Histofine	O
Antigen	O
-	O
Retrieval	O
Solution	O
(	O
1	O
:	O
10	O
dilution	O
;	O
Nichirei	O
Bioscience	O
,	O
Tokyo	O
,	O
Japan	O
)	O
for	O
10	O
minutes	O
at	O
95	O
°	O
C	O
.	O

The	O
sections	O
were	O
then	O
incubated	O
with	O
primary	O
ART3	B-GP
antibody	O
(	O
1	O
:	O
4	O
,	O
000	O
;	O
Abnova	O
,	O
Taipei	O
,	O
Taiwan	O
),	O
then	O
with	O
IgG2b	B-GP
isotype	O
(	O
1	O
:	O
4	O
,	O
000	O
;	O
MBL	O
International	O
,	O
Woburn	O
,	O
USA	O
)	O
for	O
60	O
minutes	O
at	O
room	O
temperature	O
.	O

After	O
washing	O
with	O
PBS	O
,	O
the	O
sections	O
were	O
incubated	O
with	O
the	O
Histofine	O
Simple	O
Stain	O
Max	O
-	O
PO	O
(	O
Multi	O
)	O
(	O
1	O
:	O
5	O
dilution	O
;	O
Nichirei	O
Bioscience	O
)	O
for	O
30	O
minutes	O
at	O
room	O
temperature	O
,	O
and	O
then	O
reacted	O
with	O
DAB	O
(	O
Nichirei	O
Bioscience	O
)	O
for	O
10	O
minutes	O
at	O
room	O
temperature	O
.	O

Haematoxylin	O
was	O
used	O
for	O
counterstaining	O
.	O

Supporting	O
Information	O

Statistical	O
Analysis	O
Reveals	O
Transcripts	O
Differentially	O
Expressed	O
among	O
Three	O
NOA	O
Subclasses	O

Venn	O
diagram	O
summaries	O
show	O
the	O
number	O
of	O
transcripts	O
differentially	O
expressed	O
with	O
significance	O
by	O
Tukey	O
'	O
s	O
post	O
hoc	O
test	O
in	O
each	O
comparison	O
(	O
see	O
Table	O
S1	O
)	O

(	O
694	O
KB	O
EPS	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Comparisons	O
of	O
Expression	O
Levels	O
of	O
149	O
Transcripts	O
Expressed	O
Differentially	O
between	O
Three	O
NOA	O
Subclasses	O
in	O
Microarray	O
Analysis	O
(	O
Part	O
I	O
)	O

Natural	O
log	O
-	O
transformed	O
normalized	O
ratios	O
of	O
NOA	O
to	O
testis	O
reference	O
(	O
y	O
-	O
axes	O
)	O
were	O
subjected	O
to	O
statistical	O
analysis	O
,	O
as	O
described	O
in	O
Materials	O
and	O
Methods	O
.	O

Each	O
column	O
represents	O
mean	O
±	O
standard	O
error	O
of	O
the	O
mean	O
.	O

The	O
53	O
transcripts	O
with	O
highly	O
significant	O
(	O
p	O
<	O
0	O
.	O
01	O
,	O
Tukey	O
test	O
)	O
differences	O
between	O
the	O
three	O
NOA	O
subclasses	O
are	O
shown	O
in	O
red	O
.	O

(	O
773	O
KB	O
EPS	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Comparisons	O
of	O
Expression	O
Levels	O
of	O
149	O
Transcripts	O
Expressed	O
Differentially	O
between	O
Three	O
NOA	O
Subclasses	O
in	O
Microarray	O
Analysis	O
(	O
Part	O
II	O
)	O

Natural	O
log	O
-	O
transformed	O
normalized	O
ratios	O
of	O
NOA	O
to	O
testis	O
reference	O
(	O
y	O
-	O
axes	O
)	O
were	O
subjected	O
to	O
statistical	O
analysis	O
,	O
as	O
described	O
in	O
Materials	O
and	O
Methods	O
.	O

Each	O
column	O
represents	O
mean	O
±	O
standard	O
error	O
of	O
the	O
mean	O
.	O

The	O
53	O
transcripts	O
with	O
highly	O
significant	O
(	O
p	O
<	O
0	O
.	O
01	O
,	O
Tukey	O
test	O
)	O
differences	O
between	O
the	O
three	O
NOA	O
subclasses	O
are	O
shown	O
in	O
red	O
.	O

(	O
798	O
KB	O
EPS	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Comparisons	O
of	O
Expression	O
Levels	O
of	O
149	O
Transcripts	O
Expressed	O
Differentially	O
between	O
Three	O
NOA	O
Subclasses	O
in	O
Microarray	O
Analysis	O
(	O
Part	O
III	O
)	O

Natural	O
log	O
-	O
transformed	O
normalized	O
ratios	O
of	O
NOA	O
to	O
testis	O
reference	O
(	O
y	O
-	O
axes	O
)	O
were	O
subjected	O
to	O
statistical	O
analysis	O
,	O
as	O
described	O
in	O
Materials	O
and	O
Methods	O
.	O

Each	O
column	O
represents	O
mean	O
±	O
standard	O
error	O
of	O
the	O
mean	O
.	O

The	O
53	O
transcripts	O
with	O
highly	O
significant	O
(	O
p	O
<	O
0	O
.	O
01	O
,	O
Tukey	O
test	O
)	O
differences	O
between	O
the	O
three	O
NOA	O
subclasses	O
are	O
shown	O
in	O
red	O
.	O

(	O
822	O
KB	O
EPS	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Correlations	O
of	O
Testicular	O
Gene	O
Expression	O
Evaluated	O
by	O
Microarray	O
and	O
Quantitative	O
Real	O
-	O
Time	O
RT	O
-	O
PCR	O
Analyses	O

Expression	O
levels	O
of	O
51	O
transcripts	O
with	O
highly	O
significant	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
differences	O
in	O
expression	O
among	O
the	O
three	O
NOA	O
subclasses	O
were	O
quantified	O
by	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
method	O
as	O
described	O
in	O
Material	O
and	O
Methods	O
.	O

Squares	O
of	O
correlation	O
coefficients	O
(	O
R	O
2	O
)	O
for	O
the	O
respective	O
transcripts	O
were	O
calculated	O
between	O
normalized	O
expression	O
ratios	O
of	O
NOA	O
to	O
testis	O
reference	O
in	O
microarray	O
data	O
(	O
x	O
-	O
axes	O
)	O
and	O
the	O
corresponding	O
ratios	O
obtained	O
by	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
analysis	O
(	O
y	O
-	O
axes	O
)	O

(	O
1	O
.	O
7	O
MB	O
EPS	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

149	O
Transcripts	O
Representing	O
Statistically	O
Significant	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
Differences	O
in	O
Testicular	O
Expression	O
between	O
Three	O
NOA	O
Subclasses	O

(	O
68	O
KB	O
XLS	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Comparison	O
of	O
Minor	O
Allele	O
Frequencies	O
(	O
MAFs	O
)	O
at	O
191	O
SNPs	O
of	O
42	O
Genes	O
between	O
190	O
Infertile	B-DS
Patients	O
and	O
190	O
Fertile	O
Males	O
(	O
First	O
Round	O
of	O
Initial	O
Screening	O
)	O

(	O
415	O
KB	O
DOC	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Quantitative	O
Real	O
-	O
time	O
RT	O
-	O
PCR	O
Assays	O
for	O
51	O
Transcripts	O
Representing	O
Highly	O
Significant	O
Differences	O
between	O
NOA	O
Subclasses	O

(	O
30	O
KB	O
XLS	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Author	O
contributions	O
.	O
AT	O
,	O
KT	O
,	O
and	O
II	O
conceived	O
and	O
designed	O
the	O
experiments	O
.	O

HO	O
and	O
AT	O
performed	O
the	O
experiments	O
and	O
analyzed	O
the	O
data	O
.	O

AT	O
,	O
KS	O
,	O
KT	O
,	O
and	O
II	O
contributed	O
reagents	O
/	O
materials	O
/	O
analysis	O
tools	O
.	O

HO	O
,	O
AT	O
,	O
and	O
II	O
wrote	O
the	O
manuscript	O
.	O

All	O
authors	O
contributed	O
to	O
editing	O
the	O
manuscript	O
.	O

HO	O
and	O
AT	O
have	O
joint	O
authorship	O
of	O
this	O
manuscript	O
.	O

Competing	O
interests	O
.	O
The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

